Biora Therapeutics (BIOR) 10-Q 9 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Oct. 31, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Registrant Name	PROGENITY, INC.
Entity Central Index Key	0001580063
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,976,277
Entity File Number	001-39334
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-3950390
Entity Address, Address Line One	4330 La Jolla Village Drive
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92122
City Area Code	855
Local Phone Number	293-2639
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	PROG
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 60,013	$ 33,042
Accounts receivable, net	13,425	22,189
Inventory	10,383	10,937
Income tax receivable		634
Prepaid expenses and other current assets	9,216	7,846
Total current assets	93,037	74,648
Property and equipment, net	16,088	15,891
Other assets	198	198
Goodwill	6,219	6,219
Other intangible assets, net	4,075	4,771
Total assets	119,617	101,727
Current liabilities:
Accounts payable	15,666	15,754
Accrued expenses and other current liabilities	71,013	83,615
Current portion of mortgages payable	268	241
Current portion of capital lease obligations	399	727
Total current liabilities	87,346	100,337
Capital lease obligations, net of current portion	97	358
Mortgages payable, net of current portion	2,864	3,081
Note payable to related party, net of unamortized discount of $5,358 and $6,034 as of September 30, 2020 and December 31, 2019, respectively	69,642	68,966
Other long-term liabilities	20,088	12,859
Total liabilities	180,037	185,601
Commitments and contingencies
Stockholders' deficit:
Common stock – $0.001 par value. 350,000,000 and 300,000,000 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 50,450,849 and 8,451,415 shares issued as of September 30, 2020 and December 31, 2019, respectively; 46,976,277 and 4,976,843 shares outstanding as of September 30, 2020 and December 31, 2019, respectively	50	9
Additional paid-in capital	424,047	283,260
Accumulated deficit	(465,746)	(348,478)
Treasury stock – at cost; 3,474,572 shares of common stock as of September 30, 2020 and December 31, 2019	(18,771)	(18,771)
Total stockholders' deficit	(60,420)	(83,874)
Total liabilities and stockholders' deficit	$ 119,617	101,727
Series A Preferred Stock
Stockholders' deficit:
Preferred Stock		4
Series B Preferred Stock
Stockholders' deficit:
Preferred Stock		$ 102

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Note payable, unamortized discount	$ 5,358	$ 6,034
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	300,000,000
Common stock, shares issued	50,450,849	8,451,415
Common stock, shares outstanding	46,976,277	4,976,843
Preferred stock, shares authorized	10,000,000	130,155,000
Treasury stock, at cost shares	3,474,572	3,474,572
Series A Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	0	4,120,000
Preferred stock, shares issued	0	4,120,000
Preferred stock, shares outstanding	0	4,120,000
Series B Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	0	126,035,000
Preferred stock, shares issued	0	101,867,405
Preferred stock, shares outstanding	0	101,867,405

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues	$ 25,943	$ 18,772	$ 60,037	$ 123,509
Cost of sales	23,601	24,997	72,006	75,531
Gross profit (loss)	2,342	(6,225)	(11,969)	47,978
Operating expenses:
Research and development	13,043	17,080	36,517	48,791
Selling and marketing	13,244	15,263	40,416	45,510
General and administrative	20,626	16,273	54,915	44,823
Total operating expenses	46,913	48,616	131,848	139,124
Loss from operations	(44,571)	(54,841)	(143,817)	(91,146)
Interest expense	(2,476)	(2,321)	(7,285)	(6,872)
Interest and other income (expense), net	(18)	29	(3,594)	457
Loss before income taxes	(47,065)	(57,133)	(154,696)	(97,561)
Income tax benefit			(37,696)
Net loss	(47,065)	(57,133)	(117,000)	(97,561)
Dividend paid to preferred stockholders			(268)	(3,652)
Stock dividend on exchange of Series A-1 to Series B Preferred Stock		(27,637)		(27,637)
Stock dividend on Series B Preferred Stock		(13,137)		(13,137)
Net loss attributable to common stockholders	$ (47,065)	$ (97,907)	$ (117,268)	$ (141,987)
Net loss per share attributable to common stockholders, basic and diluted	$ (1.01)	$ (19.85)	$ (5.80)	$ (29.27)
Weighted average number of shares outstanding used in calculating net loss per share attributable to common stockholders, basic and diluted	46,632,043	4,931,204	20,201,325	4,851,603

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Initial Public Offering	Cumulative effect, period of adoption, adjustment	Common Stock	Common StockInitial Public Offering	Preferred StockSeries A and A-1 Preferred Stock	Preferred StockSeries B Preferred Stock	Additional Paid-In Capital	Additional Paid-In CapitalInitial Public Offering	Accumulated Deficit	Accumulated DeficitCumulative effect, period of adoption, adjustment	Treasury Stock
Beginning Balance at Dec. 31, 2018	$ (36,968)			$ 8		$ 6	$ 14	$ 124,244		$ (142,469)		$ (18,771)
Beginning Balance, shares at Dec. 31, 2018				8,112,581		5,620,000	14,164,306					(3,474,572)
Issuance of common stock upon exercise of options	322							322
Issuance of common stock upon exercise, shares				268,549
Stock-based compensation expense	555							555
Dividends paid	(4,500)									(4,500)
Net loss	(24,019)									(24,019)
Ending Balance at Mar. 31, 2019	(40,944)		$ 23,666	$ 8		$ 6	$ 14	125,121		(147,322)	$ 23,666	$ (18,771)
Ending Balance, shares at Mar. 31, 2019				8,381,130		5,620,000	14,164,306					(3,474,572)
Beginning Balance at Dec. 31, 2018	(36,968)			$ 8		$ 6	$ 14	124,244		(142,469)		$ (18,771)
Beginning Balance, shares at Dec. 31, 2018				8,112,581		5,620,000	14,164,306					(3,474,572)
Net loss	(97,561)
Ending Balance at Sep. 30, 2019	(89,067)			$ 8		$ 4	$ 63	191,267		(261,638)		$ (18,771)
Ending Balance, shares at Sep. 30, 2019				8,447,926		4,120,000	62,936,969					(3,474,572)
Beginning Balance at Mar. 31, 2019	(40,944)		$ 23,666	$ 8		$ 6	$ 14	125,121		(147,322)	$ 23,666	$ (18,771)
Beginning Balance, shares at Mar. 31, 2019				8,381,130		5,620,000	14,164,306					(3,474,572)
Issuance of common stock upon exercise of options	120							120
Issuance of common stock upon exercise, shares				15,936
Stock-based compensation expense	597							597
Net loss	(16,409)									(16,409)
Ending Balance at Jun. 30, 2019	(56,636)			$ 8		$ 6	$ 14	125,838		(163,731)		$ (18,771)
Ending Balance, shares at Jun. 30, 2019				8,397,066		5,620,000	14,164,306					(3,474,572)
Issuance of common stock upon exercise of options	88							88
Issuance of common stock upon exercise, shares				50,860
Exchange of Series A-1 Preferred Stock to Series B Preferred Stock of restricted stock unit awards						$ (2)	$ 36	27,603		(27,637)
Exchange of Series A-1 Preferred Stock to Series B Preferred Stock of restricted stock unit awards, shares						(1,500,000)	35,664,241
Issuance of stock, net	23,983						$ 9	23,974
Issuance of stock, net, shares							9,090,910
Stock dividend on Series B Preferred Stock							$ 4	13,133		(13,137)
Stock dividend on Series B Preferred Stock, shares							4,017,512
Stock-based compensation expense	631							631
Net loss	(57,133)									(57,133)
Ending Balance at Sep. 30, 2019	(89,067)			$ 8		$ 4	$ 63	191,267		(261,638)		$ (18,771)
Ending Balance, shares at Sep. 30, 2019				8,447,926		4,120,000	62,936,969					(3,474,572)
Beginning Balance at Dec. 31, 2019	(83,874)			$ 9		$ 4	$ 102	283,260		(348,478)		$ (18,771)
Beginning Balance, shares at Dec. 31, 2019				8,451,415		4,120,000	101,867,405					(3,474,572)
Issuance of common stock upon exercise of options	103							103
Issuance of common stock upon exercise, shares				56,729
Issuance of stock, net	14,072						$ 6	14,066
Issuance of stock, net, shares							6,033,796
Stock-based compensation expense	2,057							2,057
Net loss	(17,152)									(17,152)
Ending Balance at Mar. 31, 2020	(84,794)			$ 9		$ 4	$ 108	299,486		(365,630)		$ (18,771)
Ending Balance, shares at Mar. 31, 2020				8,508,144		4,120,000	107,901,201					(3,474,572)
Beginning Balance at Dec. 31, 2019	$ (83,874)			$ 9		$ 4	$ 102	283,260		(348,478)		$ (18,771)
Beginning Balance, shares at Dec. 31, 2019				8,451,415		4,120,000	101,867,405					(3,474,572)
Issuance of common stock upon exercise, shares	505,852
Net loss	$ (117,000)
Ending Balance at Sep. 30, 2020	(60,420)			$ 50				424,047		(465,746)		$ (18,771)
Ending Balance, shares at Sep. 30, 2020				50,450,849								(3,474,572)
Beginning Balance at Mar. 31, 2020	(84,794)			$ 9		$ 4	$ 108	299,486		(365,630)		$ (18,771)
Beginning Balance, shares at Mar. 31, 2020				8,508,144		4,120,000	107,901,201					(3,474,572)
Issuance of common stock upon exercise of options	45							45
Issuance of common stock upon exercise, shares				20,880
Issuance of stock, net	9,933	$ 88,665			$ 7		$ 4	9,929	$ 88,658
Issuance of stock, net, shares					6,666,667		4,444,444
Automatic conversion of preferred stock				$ 33		$ (4)	$ (112)	83
Automatic conversion of preferred stock, shares				33,443,562		(4,120,000)	(112,345,645)
Issuance of common stock upon conversion of debt	18,750			$ 1				18,749
Issuance of common stock upon conversion of debt, shares				1,250,000
Issuance of Stock Purchase Warrants								268		(268)
Issuance of common stock upon vesting of restricted stock unit awards, shares				133,353
Stock-based compensation expense	3,024							3,024
Net loss	(52,783)									(52,783)
Ending Balance at Jun. 30, 2020	(17,160)			$ 50				420,242		(418,681)		$ (18,771)
Ending Balance, shares at Jun. 30, 2020				50,022,606								(3,474,572)
Issuance of common stock upon exercise of options	431							431
Issuance of common stock upon exercise, shares				428,243
Stock-based compensation expense	3,374							3,374
Net loss	(47,065)									(47,065)
Ending Balance at Sep. 30, 2020	$ (60,420)			$ 50				$ 424,047		$ (465,746)		$ (18,771)
Ending Balance, shares at Sep. 30, 2020				50,450,849								(3,474,572)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating Activities:
Net loss	$ (117,000)	$ (97,561)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash revenue reserve	22,848	19,935
Depreciation and amortization	3,762	3,480
Stock-based compensation expense	8,455	1,783
Loss on extinguishment of convertible note	3,401
Amortization of debt discount	1,902	1,229
Inventory write-down	80	120
Loss on disposal of property and equipment	67
Change in fair value of derivative liability	126
Changes in operating assets and liabilities:
Accounts receivable, net	8,765	695
Inventory	475	(3,675)
Income tax receivable	635	6,173
Prepaid expenses and other current assets	(2,420)	(2,588)
Other assets		(62)
Accounts payables	1,441	10,729
Accrued expenses and other liabilities	(29,807)	(537)
Other long-term liabilities	1,583
Net cash used in operating activities	(95,687)	(60,279)
Investing Activities:
Purchases of property and equipment	(3,109)	(2,917)
Purchases of short-term investments		(11,214)
Proceeds from sale of short-term investments		31,414
Proceeds from sale of equity method investment		50
Net cash (used in) provided by investing activities	(3,109)	17,333
Financing Activities:
Proceeds from issuance of common stock, net	90,344	530
Proceeds from issuance of Series B Preferred Stock, net	21,307	24,967
Proceeds from issuance of convertible note, net	14,895
Dividends paid		(4,500)
Principal payments on mortgages payable	(190)	(172)
Principal payments on capital lease obligations	(589)	(834)
Net cash provided by financing activities	125,767	19,991
Net increase (decrease) in cash and cash equivalents	26,971	(22,955)
Cash and cash equivalents at beginning of period	33,042	49,005
Cash and cash equivalents at end of period	60,013	26,050
Supplemental disclosure of cash flow information:
Cash paid for interest	3,765	5,642
Cash paid for income taxes	58	6
Supplemental schedule of non-cash investing and financing activities:
Conversion of convertible note	18,750
Issuance of preferred stock in settlement of interest payable	2,698
Equity offering costs incurred but not paid	1,101	984
Issuance of stock options in settlement of accrued bonuses	754
Purchases of property and equipment in accounts payable	$ 220	240
Capital lease obligations		229
Stock dividend on exchange of Series A-1 to Series B Preferred Stock		27,367
Stock dividend on Series B Preferred Stock		$ 13,137

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Progenity, Inc. (the “Company” or “Progenity”), a Delaware corporation, commenced operations in 2010 with its corporate office located in San Diego, California. Progenity’s primary operations include a licensed Clinical License Improvement Amendment and College of American Pathologists certified laboratory located in Michigan specializing in the molecular testing markets serving women’s health providers in the obstetric, gynecological, fertility, and maternal fetal medicine specialty areas in the United States. The Company has expertise in the national reference laboratory, clinical genetics, laboratory molecular testing, and biotechnology markets. Distribution is managed by a dedicated women’s health physician sales force and a field operations team who support all logistical functions in receiving clinical samples to the laboratory for analysis. The Company’s core business is focused on the prenatal carrier screening and noninvasive prenatal test market, targeting preconception planning, and routine pregnancy management for genetic disease risk assessment. Through its affiliation with Mattison Pathology, LLP (“Mattison”), a Texas limited liability partnership doing business as Avero Diagnostics (“Avero”), located in Lubbock and Dallas, Texas, the Company’s operations have expanded to provide anatomic and molecular pathology testing products in the United States. On June 10, 2020, the Company amended its certificate of incorporation to reflect a one-for-6.178 reverse stock split of the Company’s common stock. The par value and the number of authorized shares of common stock were not adjusted as a result of the reverse stock split. All issued and outstanding shares of common stock and related per share amounts contained in the accompanying condensed consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split resulted in an adjustment to the respective Series A and B preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. On June 23, 2020, the Company completed the initial public offering of its common stock (the “IPO”). In the IPO, the Company issued and sold 6,666,667 shares of its common stock, at a price to the public of $15.00 per share. The Company received approximately $88.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses payable by the Company. In connection with the IPO, on June 23, 2020, all outstanding Series A and B preferred stock and the outstanding convertible promissory note converted into shares of common stock and the outstanding warrant to purchase shares of convertible preferred stock became exercisable for shares of common stock. Liquidity As of September 30, 2020, the Company had cash and cash equivalents of $60.0 million and an accumulated deficit of $465.7 million. For the nine months ended September 30, 2020, the Company reported a net loss of $117.0 million and cash used in operating activities of $95.7 million. The Company’s primary sources of capital have historically been the sale of common stock, or from other potential sources of liquidity, which may include new collaborations, licensing or other commercial agreements for one or more of the Company’s research programs or patent portfolios ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. Uncertainties Related to the COVID-19 Pandemic The ongoing COVID‑19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. The Company has been materially and negatively affected by the COVID-19 pandemic; however, the extent of the impact of the COVID-19 pandemic on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, including the duration and spread of the pandemic and related restrictions on travel and transports, all of which are uncertain and cannot be predicted. The Company could be further negatively affected by the widespread outbreak of an illness or any other communicable disease, or any other public health crisis that results in economic and trade disruptions, including the disruption of global supply chains. An extended period of global supply chain and economic disruption could materially affect the Company’s business, results of operations, access to sources of liquidity and financial condition. The estimates used for, but not limited to, determining the amount to be collected for accounts receivable, fair value of long-lived assets, and fair value of goodwill could be impacted by the pandemic. While the full impact of COVID-19 is unknown at this time, the Company has made appropriate estimates based on the facts and circumstances available as of the reporting date. These estimates may change as new events occur and additional information is obtained.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) fo r interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. he Company’s final prospectus filed with the Securities and Exchange Commission on June 22, 2020 Unaudited Interim Financial Information The accompanying condensed consolidated balance sheet as of September 30, 2020, the statements of operations and the statements of stockholders’ deficit for the three and nine months ended September 30, 2020 and 2019 and the statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, that are necessary for the fair statement of the Company’s financial position as of September 30, 2020, and the results of its operations and its cash flows for the three and nine months ended September 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2020 and 2019 are also unaudited. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period, particularly in light of the COVID-19 pandemic and its impact on domestic and global economies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include the estimate of variable consideration in connection with the recognition of revenue, the valuation of Series B preferred stock, the valuation of stock options, the valuation of goodwill and intangible assets, accrual for reimbursement claims and settlements, assessing future tax exposure and the realization of deferred tax assets, the useful lives and the recoverability of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. All revenues are attributable to U.S.-based operations and all assets are held in the United States. Revenue Recognition Revenue is recognized in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Revenue is primarily derived from providing molecular testing products, which are reimbursed through arrangements with third-party payors, laboratory distribution partners, and amounts from individual patients. Third-party payors include commercial payors, such as health insurance companies, health maintenance organizations and government health benefit programs, such as Medicare and Medicaid. The Company’s contracts generally contain a single performance obligation, which is the delivery of the test results, and the Company satisfies its performance obligation at a point in time upon the delivery of the results, which then triggers the billing for the product. The amount of revenue recognized reflects the amount of consideration the Company expects to be entitled to (the “transaction price”) and considers the effects of variable consideration. Revenue is recognized when control of the promised product is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products. The Company applies the following practical expedients and exemptions: • Incremental costs incurred to obtain a contract are expensed as incurred because the related amortization period would have been one year or less. The costs are included in selling and marketing expenses. • No adjustments to amounts of promised consideration are made for the effects of a significant financing component because the Company expects, at contract inception, that the period between the transfer of a promised good or service and customer payment for that good or service will be one year or less. Payor Concentration The Company relies upon reimbursements from third-party government payors and private-payor insurance companies to collect accounts receivable. The Company’s significant third-party payors and their related accounts receivable balances and revenues as a percentage of total accounts receivable balances and revenues are as follows: Percentage of Accounts Receivable September 30, 2020 December 31, 2019 Blue Shield of Texas 21.4 % 0.1 % Government Health Benefits Programs 20.5 % 16.7 % Aetna 6.4 % 6.0 % United Healthcare 5.7 % 31.5 % Percentage of Revenue Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Blue Shield of Texas 26.5 % 47.2 % 35.4 % 19.4 % Government Health Benefits Programs(1) 21.9 % (29.4 )% (5.6 )% 9.3 % Aetna 7.9 % 10.7 % 10.7 % 8.1 % United Healthcare 5.5 % 28.8 % 4.9 % 30.9 % ____________ (1) The negative amounts presented in the percentage of revenues include accruals for reimbursement claims and settlements included in the estimates of variable consideration recorded during the three and nine months ended September 30, 2020 and 2019. Revenue recognized consider the effects of variable consideration, and include adjustments for estimates of disallowed cases, discounts, and refunds. The variable consideration includes reductions in revenues for the accrual for reimbursement claims and settlements, as described in Notes 4 and 9. Accounts Receivable Accounts receivable is recorded at the transaction price and considers the effects of variable consideration. The total consideration the Company expects to collect is an estimate and may be fixed or variable. Variable consideration includes reimbursement from third-party payors, laboratory distribution partners, and amounts from individual patients, and is adjusted for disallowed cases, discounts, and refunds using the expected value approach. The Company monitors these estimates at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Net Loss Per Share Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The Company considers all series of preferred stock to be participating securities as the holders of such stock are entitled to receive non-cumulative dividends on an as-converted basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stockholders is not allocated to the preferred stock as the holders of preferred stock do not have a contractual obligation to share in the Company’s losses. Under the two-class method, net income is attributed to common stockholders and participating securities based on their participation rights. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net loss attributable to common stockholders is calculated by adjusting net loss with dividends to preferred stockholders, if any. As the Company has reported net losses for all periods presented, all potentially dilutive securities are antidilutive and, accordingly, basic net loss per share equals diluted net loss per share. Comprehensive Loss The Company did not have any other comprehensive income or loss for any of the periods presented, and therefore comprehensive loss was the same as the Company’s net loss. Recent Accounting Pronouncements Adopted In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Accounting for Income Taxes Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Leases (Topic 840) Leases (Topic 842): Effective Dates The Company plans to adopt the new lease standard effective January 1, 2021, using the effective date method with the cumulative effect of the change reflected in retained earnings as of January 1, 2021, if any. The Company plans to elect the package of practical expedients available in the new lease standard, allowing it not to reassess: (a) whether expired or existing contracts contain leases under the new definition of a lease; (b) lease classification for expired or existing leases; and (c) whether previously capitalized initial direct costs would qualify for capitalization under the new lease standard. The Company continues to monitor FASB activity to assess certain interpretative issues and the associated implementation of the new standard and is in the process of reviewing its lease arrangements, including property, equipment and vehicle leases. The Company is not yet able to estimate the anticipated impact to its consolidated financial statements from the implementation of the new standard as it continues to interpret the principles of the new standard. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses Codification Improvements to Topic 326, Financing Instruments–Credit Losses In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment

Variable Interest Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2020
Text Block [Abstract]
Variable Interest Entity	3. Variable Interest Entity In June 2015, the Company entered into a series of agreements with Avero. The Company entered into a purchase agreement to acquire certain assets from Mattison used in the operations of Avero. The purchase agreement was accounted for under the acquisition method in accordance with the provisions of ASC Topic 805, Business Combinations The Company also entered into a management services arrangement that authorizes the Company to perform the management services in the manner that it deems reasonably appropriate to meet the day-to-day business needs of Avero. The Company’s management services include funding ongoing operational needs, directing activities related to contract negotiation, billing, human resources, and legal and administrative matters and processes, among others. In exchange for the management services provided, the Company is entitled to receive an annual management fee equal to the amount of the net operating income of Avero. The term of the agreement with Avero is 10 years, subject to automatic renewals. The agreement can be terminated by either party with a 90-day notice before the end of the term. Through the management services arrangement with Avero, the Company has (1) the power to direct the activities of Avero that most significantly impact its economic performance, and (2) the obligation to absorb losses of Avero or the right to receive benefits from Avero that could potentially be significant to Avero. Based on these determinations, the Company has determined that Avero is a variable interest entity and that the Company is the primary beneficiary. The Company does not own any equity interest in Avero; however, as these agreements provide the Company the controlling financial interest in Avero, the Company consolidates Avero’s balances and activities within its consolidated financial statements. In December 2018, Avero entered into a settlement agreement with Cigna (the “Cigna settlement obligation”) whereby Avero agreed to pay an aggregate amount of $12.0 million with an upfront payment of $6.0 million and the remaining $6.0 million to be paid over 24 months, beginning in February 2019. The Company guaranteed the $12.0 million Cigna settlement obligation. The Company provided financial support to Avero in the amount of $0.8 million and $2.3 million during the three and nine months ended September 30, 2020, respectively, and $0.8 million and $2.3 million during the three and nine months ended September 30, 2019, respectively, related to the Cigna settlement obligation (see Note 9). The Company did not provide any additional financial support to Avero during the three and nine months ended September 30, 2020 and 2019, other than the Cigna settlement obligation and agreed upon management services. The following table presents the assets and liabilities of Avero that are included in the Company’s condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, in thousands. The creditors of Avero have no recourse to the general credit of the Company, with the exception of $1.8 million and $1.9 million in mortgage payable guaranteed by the Company as of September 30, 2020 and December 31, 2019, respectively (see Note 8), and $0.8 million and $3.0 million in remaining Cigna settlement obligation guaranteed by the Company as of September 30, 2020 and December 31, 2019, respectively. The assets and liabilities exclude intercompany balances that eliminate in consolidation: September 30, 2020 December 31, 2019 Assets of Avero that can only be used to settle obligations of Avero Cash and cash equivalents $ 1,038 $ 1,837 Accounts receivable, net 4,733 4,269 Inventory 2,143 2,572 Prepaid expenses and other current assets 1,093 1,181 Property and equipment, net 5,486 5,586 Other assets 30 30 Goodwill 6,219 6,219 Other intangible assets, net 4,075 4,771 Total assets of Avero that can only be used to settle obligations of Avero $ 24,817 $ 26,465 Liabilities of Avero Accounts payable $ 3,166 $ 2,450 Accrued expenses and other accrued liabilities 3,609 5,630 Current portion of capital lease obligations 49 59 Current portion of mortgage payable 197 173 Capital lease obligations, net of current portion 16 50 Mortgage payable, net of current portion 1,570 1,733 Other long-term liabilities 571 467 Total liabilities of Avero $ 9,178 $ 10,562

Revenues

Revenues	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenues	4. Revenues Revenue is derived from contracts with healthcare insurers, government payors, laboratory partners and patients in connection with sales of prenatal genetic, anatomic or molecular pathology tests. The Company enters into contracts with healthcare insurers related to tests provided to patients who have health insurance coverage. Insurance carriers are considered third-party payors on behalf of the patients, and the patients who receive genetic, anatomic or molecular pathology test products are considered the customers. Tests may be billed to insurance carriers, patients, or a combination of insurance carriers and patients. The Company also sells tests to laboratory partners, which are also considered to be customers. The Company’s test volumes began to decrease in the second half of March 2020 as a result of the COVID-19 pandemic spreading in the United States and resulting limitations and reordering of priorities across the U.S. healthcare system. The Company expects test volumes to continue to be adversely affected by COVID-19 and cannot predict when volumes will return to normal. In accordance with ASC 606, a performance obligation represents a promise in a contract to transfer a distinct good or service to a customer and the consideration should be allocated to each distinct performance obligation and recognized as revenue when or as the performance obligation is satisfied. The Company has evaluated its contracts with healthcare insurers, government payors, laboratory partners and patients and identified a single performance obligation in those contracts, the delivery of a test result. The Company satisfies its performance obligation at a point in time upon the delivery of the test result, at which point the Company can bill for its products. The amount of revenue recognized reflects the transaction price and considers the effects of variable consideration, which is discussed below. Once the Company satisfies its performance obligations upon delivery of a test result and bills for the product, the timing of the collection of payments may vary based on the payment practices of the third-party payor. The Company bills patients directly for co-pays and deductibles that they are responsible for and also bills patients directly in cases where the customer does not have insurance. The Company has established an accrual for refunds of payments previously made by healthcare insurers based on historical experience and executed settlement agreements with healthcare insurers. The refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. For example, during the three months ended June 30, 2020, the Company accrued $10.3 million for refunds to government payors related to reimbursement for the Company’s Preparent expanded carrier screening tests during 2019 and early 2020. In the United States, the American Medical Association (“AMA”) generally assigns specific billing codes for laboratory tests under a coding system known as Current Procedure Terminology (“CPT”), which the Company and its ordering healthcare providers must use to bill and receive for molecular tests. The transaction price is an estimate and may be fixed or variable. Variable consideration includes reimbursement from healthcare insurers, government payors, and patients and is adjusted for estimates of disallowed cases, discounts, and refunds using the expected value approach. Tests billed to healthcare insurers and directly to patients can take up to nine months to collect and the Company may be paid less than the full amount billed or not paid at all. For insurance carriers and government payors, management utilizes the expected value method using a portfolio of relevant historical data for payors with similar reimbursement characteristics. The portfolio estimate is developed using historical reimbursement data from payors and patients, as well as known current reimbursement trends not reflected in the historical data. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company monitors these estimates at each reporting period based on actual cash collections and the status of settlement agreements with third-party payors, in order to assess whether a revision to the estimate is required. Both the initial estimate and any subsequent revision to the estimate contain uncertainty and require the use of judgment in the estimation of the transaction price and application of the constraint for variable consideration. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect revenue and earnings in the period such variances become known. The consideration expected from laboratory partners is generally a fixed amount. The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in an additional $3.3 million and a reduction of $19.4 million of revenue reported for the three and nine months ended September 30, 2020, respectively, and a reduction of $17.8 million and an additional $1.0 million of revenue reported for the three and nine months ended September 30, 2019, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements described in Note 9. Disaggregation of Revenues The following table shows a further disaggregation of revenues by payor type (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Commercial third-party payors $ 18,555 $ 23,058 $ 58,148 $ 108,851 Government health benefit programs(1) 5,692 (5,513 ) (3,374 ) 11,432 Patient/laboratory distribution partners 1,696 1,227 5,263 3,226 Total revenues $ 25,943 $ 18,772 $ 60,037 $ 123,509 ____________ (1) The revenue amounts include accruals for reimbursement claims and settlements included in the estimates of variable consideration recorded during the three and nine months ended September 30, 2020 and 2019. Revenue recognized reflect the effects of variable consideration, and include adjustments for estimates of disallowed cases, discounts, and refunds. The variable consideration includes reductions in revenues for the accrual for reimbursement claims and settlements.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Components	5. Balance Sheet Components Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): September 30, 2020 December 31, 2019 Prepaid expenses $ 8,188 $ 6,476 Other current assets 1,028 1,370 Total $ 9,216 $ 7,846 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): September 30, 2020 December 31, 2019 Computers and software $ 13,790 $ 13,913 Building and leasehold improvements 9,458 9,491 Laboratory equipment 7,254 5,580 Furniture, fixtures, and office equipment 1,686 1,633 Construction in progress 1,891 1,493 Land 1,091 1,091 Total property and equipment 35,170 33,201 Less accumulated depreciation and amortization (19,082 ) (17,310 ) Property and equipment, net $ 16,088 $ 15,891 Capital leases included in property and equipment, net consisted of the following (in thousands): September 30, 2020 December 31, 2019 Capital leases $ 2,467 $ 3,692 Less accumulated depreciation and amortization (1,835 ) (2,239 ) Capital leases included in property and equipment, net $ 632 $ 1,453 Depreciation expense was $1.0 million and $3.1 million for the three and nine months ended September 30, 2020, respectively, and $0.9 million and $2.8 million for the three and nine months ended September 30, 2019, respectively. Intangible Assets, Net Intangible assets, net consisted of the following (in thousands): September 30, 2020 Cost Accumulated amortization Net Payor relationships $ 7,230 $ (3,856 ) $ 3,374 Trade names 1,410 (752 ) 658 Noncompete agreements 384 (341 ) 43 Intangible assets, net $ 9,024 $ (4,949 ) $ 4,075 December 31, 2019 Cost Accumulated amortization Net Payor relationships $ 7,230 $ (3,314 ) $ 3,916 Trade names 1,410 (646 ) 764 Noncompete agreements 384 (293 ) 91 Intangible assets, net $ 9,024 $ (4,253 ) $ 4,771 Amortization expense of intangible assets was $0.2 million and $0.7 million for the three and nine months ended September 30, 2020, respectively, and $0.2 million and $0.7 million for the three and nine months ended September 30, 2019, respectively. The future amortization of intangible assets at September 30, 2020 was (in thousands): Year ending December 31, Remainder of 2020 $ 232 2021 891 2022 864 2023 864 2024 864 Thereafter 360 Total future minimum lease payments $ 4,075 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accrual for reimbursement claims and settlements, current $ 47,937 $ 60,386 Commission and bonus 8,283 6,357 Vacation and payroll benefits 7,339 5,506 Accrued professional services 3,092 5,322 Contract liabilities 544 — Other 3,818 6,044 Total $ 71,013 $ 83,615 Other Long-term Liabilities Other long-term liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accrual for reimbursement claims and settlements, net of current portion $ 18,066 $ 12,205 Other 2,022 654 Total $ 20,088 $ 12,859

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements The Company's financial assets and liabilities carried at fair value are comprised of investment assets that include money market funds. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is summarized as follows: Level 1 - Quoted prices in active markets for identical assets and liabilities that the Company has the ability to access. Level 2 - Observable market-based inputs or unobservable inputs that are corroborated by market data, such as quoted prices, interest rates, and yield curves. Level 3 - Inputs that are unobservable data points that are not corroborated by market data. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value (in thousands): Quoted Prices for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2020 Money market funds(1) $ 39,737 $ — $ — December 31, 2019 Money market funds(1) $ 24,432 $ — $ — ____________ (1) Included in cash and cash equivalents in the accompanying condensed consolidated balance sheets. The Company’s policy is to recognize transfers between levels at the end of the reporting period. There were no significant transfers between Level 1 and Level 2 during the three and nine months ended September 30, 2020 and 2019. Fair Value of Financial Instruments The carrying value of the Company’s accounts receivable, income tax receivable, accounts payable, and accrued expenses and other current liabilities are considered to be representative of their respective fair values because of their short-term nature. The carrying value of the Company’s mortgages payable approximates their estimated fair value because the instruments bear interest at rates and have terms that are comparable to those available to the Company for similar loan instruments at September 30, 2020 and December 31, 2019. The carrying value of the Company’s note payable to a related party does not approximate its fair value because the instrument bears interest at a rate that is not comparable to those available to the Company for a similar loan instrument at September 30, 2020 and December 31, 2019. The carrying value and the fair value of the Company’s term loan (the “2017 Term Loan”) was $75.0 million and $80.0 million, respectively, at September 30, 2020, and $75.0 million and $79.8 million, respectively, at December 31, 2019. The carrying value of the 2017 Term Loan is presented on the accompanying condensed consolidated balance sheets net of discount on the note and debt issuance cost.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions On October 27, 2017, the Company entered into a Credit and Security Agreement and a Series B Convertible Preferred Stock Purchase Agreement with a private equity firm (the “2017 Transaction”). The 2017 Transaction provided for the 2017 Term Loan, the issuance of Series B Preferred Stock (the “Series B Preferred Stock”), and the issuance of a warrant to purchase Series B Preferred Stock (the “Series B Preferred Stock Purchase Warrant”). The 2017 Term Loan accrues interest at a rate per annum equal to 9.5% and is due October 27, 2022. The 2017 Term Loan contains customary covenants, including a requirement to maintain a minimum unrestricted cash balance at all times of at least $5.0 million. The Company is in compliance with the 2017 Term Loan covenants. The 2017 Term Loan is secured by all tangible and intangible property and assets of the Company, with the exception of its intellectual property. The total proceeds of $124.2 million from the 2017 Transaction were allocated to the 2017 Term Loan, Series B Preferred Stock, and the Series B Preferred Stock Purchase Warrant based on the relative fair value of the term loan, equity, and warrant issued. As a result, the Company allocated proceeds of $65.7 million to the 2017 Term Loan. As the proceeds allocated to the 2017 Term Loan are lower than the stated loan amount of $75.0 million, the resulting $9.3 million discount is amortized as interest expense using the effective interest method over the term of the loan. As of both September 30, 2020 and December 31, 2019, the outstanding unpaid principal under the 2017 Term Loan was $75.0 million. The unamortized discount on the 2017 Term Loan was $5.4 million and $6.0 million as of September 30, 2020 and December 31, 2019, respectively. During the three months ended September 30, 2020 and 2019, the Company recognized interest expense on the 2017 Term Loan of $2.4 million and $2.2 million, inclusive of $0.6 million and $0.4 million of discount amortization for the three months ended September 30, 2020 and 2019, respectively. During the nine months ended September 30, 2020 and 2019, the Company recognized interest expense on the 2017 Term Loan of $7.1 million and $6.6 million, inclusive of $1.7 million and $1.2 million of discount amortization for the nine months ended September 30, 2020 and 2019, respectively. In connection with the IPO, on June 18, 2020, the Series B Preferred Stock Purchase Warrant became exercisable for 400,160 shares of common stock . On March 31, 2020, the Company entered into the First Amendment to the Credit Agreement (the “Credit Agreement Amendment”), with the collateral agent and lender party thereto, providing for the payment of interest due and payable as of March 31, 2020 in shares of Series B Preferred Stock, and further providing for the payment of interest due and payable as of June 30, 2020 in shares of the Series B Preferred Stock in the event the IPO has not been consummated by such date. Pursuant to the Credit Agreement Amendment, the Company concurrently entered into a Series B Preferred Stock Subscription Agreement (the “Subscription Agreement”), with the lender, which provided for the issuance of 967,130 shares of Series B Preferred Stock at a subscription price of $2.25 per share, as payment for interest due and payable as of March 31, 2020 and all applicable fees as set forth in the Credit Agreement Amendment . On May 8, 2020, the Company entered into an unsecured convertible promissory note (the “Note”) with an existing investor pursuant to a note purchase agreement, in an aggregate principal amount of $15.0 million, with an annual interest rate of 8.0% and a maturity date of May 8, 2022. The Note was convertible into (i) common stock upon an initial public offering at the lesser of the conversion price then in effect and a conversion price equal to 80% of the public offering price (or, if not a “qualified IPO” as defined in the Company’s certificate of incorporation, at the election of a majority of the holders), (ii) on the maturity date or at the election of a majority of the holders, Series B preferred stock at an initial conversion price of $13.90 per share subject to certain adjustments, or (iii) at the election of a majority of the holders, shares of another class of equity securities issued by the Company in a future financing at 80% of the price per share of such class of equity securities issued in such offering. Interest under the Note was not generally payable except that if the Note is not converted pursuant to its terms on or prior to the maturity date and there are not sufficient authorized and unissued shares of Series B preferred stock for issuance upon the conversion of the Note on the maturity date, then the Company is required to pay all outstanding principal and any accrued and unpaid interest under the Note in cash. If the holders of the Note have not elected to convert the Note prior to, or in connection with, any sale transaction or a liquidation, dissolution or winding up of the Company, either voluntary or involuntary, then, upon any such sale transaction or liquidation, dissolution or winding up of the Company, the Company would have been required to pay in cash the outstanding principal balance of the Note, together with accrued and unpaid interest thereon, plus a make whole premium of 50% of the aggregate principal amount (less accrued and unpaid interest). The Company evaluated the economic features embedded in the Note and identified features that were required to be bifurcated and accounted for separately as a derivative. Accordingly, a derivative liability of $3.6 million was recorded on the issuance date of the Note and $3.8 million was subsequently reclassified to equity representing the fair value of the derivative liability on the date of extinguishment. The change in the fair value of the derivative liability of $0.2 million is included in interest and other income (expense), net in the accompanying condensed consolidated statements of operations. In June 2020, in connection with completion of the IPO, the Note was converted into 1,250,000 shares of common stock and all obligations under the Note were extinguished. Upon the conversion, the Company recorded a $3.6 million loss on extinguishment of the debt, which represented the difference between the carrying value of the Note and the derivative liability and the fair value of the shares of common stock issued to the Note holder of $3.4 million combined with amortization of the related debt discount of $0.2 million. The loss on extinguishment of debt was included in the interest and other income (expense), net in the accompanying condensed consolidated statements of operations for nine months ended September 30, 2020.

Mortgages Payable

Mortgages Payable	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Mortgages Payable	8. Mortgages Payable In January 2014, the Company executed a mortgage with Comerica Bank for $1.8 million for the purpose of acquiring property located in Ann Arbor, Michigan, which is used for laboratory testing and research purposes. The mortgage matures in 2024 and requires monthly principal and interest payments at a fixed interest rate of 2.94% plus a floating rate at LIBOR. As of September 30, 2020 and December 31, 2019, the outstanding balance of this mortgage was $1.4 million and $1.4 million, respectively. The Company also has a mortgage with American Bank of Commerce (originally executed in February 2008) outstanding on Avero’s property located in Lubbock, Texas, which is used primarily for laboratory testing. The mortgage matures in 2029 and requires monthly principal and interest payments at an interest rate of 3.25%. As of September 30, 2020 and December 31, 2019, the outstanding balance of this mortgage was $1.8 million and $1.9 million, respectively. As of September 30, 2020, the minimum principal payments under the mortgages payable were as follows (in thousands): Year ending December 31, Minimum Mortgages Payable Payments Obligations Remainder of 2020 $ 66 2021 271 2022 281 2023 292 2024 1,338 Thereafter 884 Total future minimum payments 3,132 Less current portion of mortgages payable (268 ) Mortgages payable, net of current portion $ 2,864

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Operating Leases The Company has entered into various noncancelable operating lease agreements, primarily for office space, laboratory space, and vehicles, which expire over the next two to four years. Minimum rent payments under operating leases are recognized on a straight-line basis over the term of the lease. Rent expense for operating leases was $1.8 million and $6.0 million, for the three and nine months ended September 30, 2020, respectively, and $2.3 million and $6.6 million, respectively, for the three and nine months ended September 30, 2019. As of September 30, 2020, net minimum payments under the non-cancelable operating leases were as follows (in thousands): Year ending December 31, Minimum Operating Lease Payments Remainder of 2020 $ 1,933 2021 5,476 2022 3,017 2023 1,036 2024 and thereafter 38 Total future minimum lease payments $ 11,500 Capital Leases The Company has entered into various capital lease agreements, primarily for equipment. The outstanding leases have a weighted average imputed interest rate of 5.98% per annum. As of September 30, 2020, the future minimum payments under the capital leases were as follows (in thousands): Year ending December 31, Minimum Capital Lease Payments Remainder of 2020 $ 145 2021 324 2022 and thereafter 47 Total future minimum lease payments 516 Less amounts representing interest (20 ) Present value of minimum capital lease payments 496 Less current portion of capital lease obligations (399 ) Capital lease obligations, net of current portion $ 97 Contingencies The Company, in the ordinary course of its business, can be involved in lawsuits, threats of litigation, and audit and investigative demands from third parties. While management is unable to predict the exact outcome of such matters, it is management’s current belief, that any potential liabilities resulting from these contingencies, individually or in the aggregate, could have a material impact on the Company’s financial position and results of operations. The regulations governing government reimbursement programs (e.g., Medicaid, Tricare, and Medicare) and commercial payor reimbursement programs are complex and may be subject to interpretation. As a provider of services to patients covered under government and commercial payor programs, post payment review audits, and other forms of reviews and investigations are routine. The Company believes it complies in all material respects with the statutes, regulations, and other requirements applicable to its laboratory operations. Federal Investigations In April 2018, the Company received a civil investigative demand from an Assistant U.S. Attorney (“AUSA”) for the Southern District of New York (“SDNY”) and a Health Insurance Portability and Accountability Act subpoena issued by an AUSA for the Southern District of California (“SDCA”). In May 2018, the Company received a subpoena from the State of New York Medicaid Fraud Control Unit. On July 21, 2020, July 23, 2020, and October 1, 2020, the Company entered into agreements with certain governmental agencies and the 45 states participating in the settlement (“State AGs”) to resolve, with respect to such agencies and State AGs, all of such agencies’ and State AGs’ outstanding civil, and, where applicable, federal criminal investigations described above. Specifically, the Company has entered into: • a civil settlement agreement, effective July 23, 2020, with the DOJ through the AUSA for SDNY, and on behalf of the Office of Inspector General of the Department of Health and Human Services (the “OIG”), and with the relator named therein (the “SDNY Civil Settlement Agreement”); • a civil settlement agreement, effective July 23, 2020, with the DOJ through the AUSA for SDCA, and on behalf of the Defense Health Agency, the Tricare Program and the Office of Personnel Management, which administers the Federal Employees Health Benefits Program (the “SDCA Civil Settlement Agreement”); • a non-prosecution agreement, effective July 21, 2020, with the AUSA for SDCA (the “Non-Prosecution Agreement”) in resolution of all criminal allegations; • a corporate integrity agreement, effective July 21, 2020, with the OIG (the “Corporate Integrity Agreement”); and • civil settlement agreements, effective October 1, 2020, with the State AGs (“the State Settlement Agreements”). The Company refers to the SDNY Civil Settlement Agreement, the SDCA Civil Settlement Agreement, the Non-Prosecution Agreement, the Corporate Integrity Agreement . SDNY Civil Settlement Agreement Pursuant to the SDNY Civil Settlement Agreement, the Company is required to pay a settlement amount of approximately $19.4 million, which includes approximately $9.7 million designated as restitution to the U.S. federal government. During the three months ended September 30, 2020, the Company paid approximately $9.1 million. The Company paid an additional approximately $4.1 million subsequent to September 30, 2020, for an aggregate of approximately $13.1 million paid to date. The outstanding settlement amount is payable in three installments as follows : • approximately $1.6 million on or before December 31, 2020; • approximately $2.0 million on or before December 31, 2021; and • approximately $2.8 million on or before December 31, 2022. The remaining amounts payable to the government will be subject to interest at a rate of 1.25% per annum, and any or all amounts may be paid earlier at the option of the Company. Furthermore, the Company has agreed that, if during calendar years 2020 through 2023, and so long as amounts payable to the government remain unpaid, the Company receives any civil settlement, damages awards, or tax refunds, to the extent that the amounts exceed $5.0 million in a calendar year, it will pay 26% of the amount received in such civil settlement, damages award, or tax refunds as an accelerated payment of the scheduled amounts set forth above, up to a maximum total acceleration of $4.2 million. As previously reported, during the three months ended March 31, 2020, the Company recorded a discrete tax benefit of $37.7 million related to the net operating loss carryback provisions available under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) for taxes paid by the Company in years 2013, 2014, 2015 and 2017 (the “CARES Act Tax Benefit”). In June 2020, the Company received a tax benefit payment of approximately $22.7 million for a portion of the CARES Act Tax Benefit, and because this tax refund was received prior to the effective date of the SDNY Civil Settlement Agreement, the payment the initial settlement payment installment included an added payment of approximately $5.9 million. In addition, because the Company received a tax benefit payment of approximately $15.7 million in September 2020, and accelerated payment of approximately $4.1 million was made on October 1, 2020 with a corresponding reduction in the previously agreed upon payment term and subsequent payment amounts. Additionally, under the SDNY Civil Settlement Agreement, the U.S. federal government and the relator agreed to dismiss all civil claims asserted by the relator under the qui tam SDCA Civil Settlement Agreement The SDCA Civil Settlement Agreement requires the Company to pay a settlement amount of approximately $16.4 million, which includes approximately $10.0 million designated as restitution to the U.S. federal government. During the three months ended September 30, 2020, the Company paid approximately $7.7 million. The Company paid an additional $3.4 million subsequent to September 30, 2020, for an aggregate of $11.1 million paid to date. • approximately $1.4 million on or before December 31, 2020; • approximately $1.8 million on or before December 31, 2021; and • approximately $2.2 million on or before December 31, 2022. The remaining amounts payable to the government, will be subject to interest at a rate of 1.25% per annum, and any or all amounts may be paid earlier at the option of the Company. On July 21, 2020, the Company issued a promissory note to the U.S. federal government for the full settlement amount in connection with the SDCA Civil Settlement Agreement (the “Promissory Note”). The Promissory Note contains customary events of default and related acceleration of payment provisions. In addition, the Promissory Note provides, among other terms, that, if during calendar years 2020 through 2023, and so long as amounts payable to the government remain unpaid, the Company receives any civil settlement, damages awards, or tax refunds, to the extent that the amounts exceed $5.0 million in a calendar year, it will pay 22% of the amount received in such civil settlement, damages award, or tax refunds as an accelerated payment of the scheduled amounts set forth above up to a maximum total acceleration of approximately $3.4 million. Because the Company received a tax benefit payment of approximately $22.7 million for a portion of the CARES Act Tax Benefit in June 2020 and because this tax refund was received prior to the effective date of the Promissory Note, the initial payment installment included an added payment of $4.9 million. In addition, because the Company received a tax benefit payment of approximately $15.7 million in September 2020, an accelerated payment of approximately $3.4 million was made on October 1, 2020, with a corresponding reduction in the previously agreed upon payment term and subsequent payment amounts. Non-Prosecution Agreement Effective July 21, 2020, the Company entered into the Non-Prosecution Agreement, pursuant to which the Company agreed with the DOJ to (i) pay the restitution provided for under the SDCA Civil Settlement Agreement, (ii) not commit any felonies, (iii) continue to implement a compliance and ethics program designed to prevent and detect violations of applicable fraud and kickback laws throughout its operations and (iv) fulfill certain other disclosure, reporting and cooperation obligations. The DOJ agreed that it will not prosecute the Company for any conduct described in the Non-Prosecution Agreement provided that the Company performs its obligations under the Non-Prosecution Agreement during the period from July 21, 2020 through July 21, 2021. The Non-Prosecution Agreement provides that the DOJ may unilaterally, upon notice to the Company, extend the term of the agreement in 6-month increments, for a maximum total term of 24 months (that is, two 6-month extensions). Corporate Integrity Agreement In connection with the resolution of the investigated matters, and in exchange for the OIG’s agreement not to exercise its authority to permissively exclude the Company from participating in federal healthcare programs, effective July 21, 2020, the Company entered into a five-year Corporate Integrity Agreement with the OIG. The Corporate Integrity Agreement requires, among other matters, that the Company maintain a Compliance Officer, a Compliance Committee, board review and oversight of certain federal healthcare compliance matters, compliance programs, and disclosure programs; provide management certifications and compliance training and education; engage an independent review organization to conduct claims and arrangements reviews; and implement a risk assessment and internal review process. State Settlement Agreements Effective October 1, 2020, the Company entered into agreements with the State AGs with respect to the investigated matters. The State Settlement Agreements require the Company to pay a settlement amount of approximately $13.2 million to the participating states. above • approximately $1.1 million on or before December 31, 2020; • approximately $1.4 million on or before December 31, 2021; • approximately $1.9 million on or before December 31, 2022; and • approximately $0.2 million on or before December 31, 2023. Settlement Accruals As of December 31, 2019, the Company had accrued an aggregate of $35.8 million associated with a potential settlement with the DOJ and the participating State AGs within accrued expenses and other current liabilities and as a reduction of revenue as reflected on the consolidated balance sheet of the Company as of December 31, 2019 and consolidated statement of operations for the year ended December 31, 2019. In addition, in the quarter ended March 31, 2020, the Company accrued an additional $13.2 million with respect to the total amount to be paid under the agreement in principle to the DOJ and the participating State AGs, and additional amounts for related costs as of and for the quarterly period ended March 31, 2020. As of September 30, 2020, the Company’s accrual consists of $20.2 million in accrued expenses and other current liabilities and $12.1 million in other long-term liabilities. Payor Settlement Agreements On June 21, 2018, the Company received a letter from Cigna alleging damages related to contract terms. On December 5, 2018, Cigna and the Company entered into a settlement agreement whereby Avero agreed to pay an aggregate amount of $12.0 million with an upfront payment of $6.0 million and the remaining $6.0 million to be paid over 24 months. For the year ended December 31, 2018, the Company recorded a charge of $12.0 million associated with this claim in its consolidated statements of operations as a reduction to revenue. As of September 30, 2020, the remaining settlement accrual related to Cigna is $0.8 million included in accrued expenses and other current liabilities. On June 25, 2018, the Company received a letter from Aetna’s external legal counsel that included various allegations relating to the Company’s past practices. In November 2019, the Company and Aetna entered into a settlement agreement for $15.0 million, to be paid in installment payments through December 2020. During the year ended December 31, 2018, the Company recorded a charge of $15.0 million associated with this claim in its consolidated statements of operations as a reduction to revenue. As of September 30, 2020, the Company’s accrual consists of $5.0 million included in accrued expenses and other current liabilities. On October 18, 2018, the Company received a letter from UnitedHealth Group that included various allegations relating to the Company’s past practices. On September 30, 2019, the Company entered into a settlement agreement with United HealthCare Services, Inc. and UnitedHealthcare Insurance Company (“United”) in which the Company agreed to pay an aggregate amount of $30.0 million. The settlement is to be paid with an upfront payment of $2.0 million, and the remaining balance to be paid every six months starting December 31, 2019, with the first two installment payments of $5.0 million each, and $6.0 million each thereafter. As of September 30, 2020, the remaining settlement accrual related to United is $18.0 million consisting of $12.0 million included in accrued expenses and other current liabilities and $6.0 million included in other long-term liabilities. Payor Recoveries As noted above, the regulations governing government reimbursement programs (e.g., Medicaid, Tricare, and Medicare) and commercial payor reimbursement programs are complex and may be subject to interpretation. As a provider of services to patients covered under government reimbursement and commercial payor programs, the Company is routinely subject to post-payment review audits and other forms of reviews and investigations. If a third-party payor successfully challenges that a payment to the Company for prior testing was in breach of contract or otherwise contrary to policy or law, they may recoup such payment. The Company may also decide to negotiate and settle with a third-party payor in order to resolve an allegation of overpayment. In the ordinary course of business, the Company addresses and evaluates a number of such claims from payors. In the past, the Company has negotiated and settled these types of claims with third-party payors. The Company may be required to resolve further disputes in the future. The Company is aware of one commercial payor that is reviewing historical payments and may make a claim for recoupment in the future. While management is unable to predict the exact outcome of any such claims, it is management’s current belief that any potential liabilities resulting from these contingencies, individually or in the aggregate, could have a material impact on the Company’s financial position and results of operations. In connection with the third-party review of the Company’s coding and billing processes described in Note 4, which identified that the Company had not effectively transitioned to the implementation of the new CPT code for reimbursement for the Company’s Preparent expanded carrier screening tests during 2019 and early 2020, the Company reviewed its reimbursement from commercial payors for these tests over the same time period. The Company may need to engage with payors in order to determine if any amounts could be subject to recovery or recoupment, as it is customarily done with commercial payors. Any amounts subject to recovery or recoupment will depend on the interpretation of widely variable payor medical and billing policies. The Company will not know if any overpayments exist until it completes this engagement with individual commercial payors. If negotiations with payors result in claims or conclusions that overpayments have been made, this could have a material impact on the Company’s financial results and position. The Company is unable to predict the outcome of this matter and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome related to this matter. OIG Inquiry On October 16, 2019, the Company received an inquiry from the Texas Health & Human Services Commission Office of Inspector General (the “TX OIG”) alleging that the Company did not hold the required CLIA Laboratory Certificate of Accreditation to perform, bill for, or be reimbursed by the Texas Medicaid Program for certain tests performed by us from January 1, 2015 through December 31, 2018. Although management believes that the Company holds and have held all required CLIA certificates and/or subcontract with third-party laboratories that hold and have held such certificates to perform all of the tests subject to the TX OIG inquiry, there can be no assurance that the TX OIG will agree with this position. The Company submitted a written response to the inquiry on October 23, 2019 and are awaiting a response from the TX OIG on the matter. It is not possible to predict the outcome of these matters and the timing for resolution. Natera Lawsuit On June 17, 2020, Natera, Inc. (“Natera”) filed suit in the Western District of Texas (W.D. Texas Civil Action No. 6:20-cv-532) asserting the Company’s infringement of six Natera patents based on a portion of the Company’s NIPT product offering. On June 19, 2020, Natera filed a substantially similar second suit in the Northern District of Texas (N.D. Texas Civil Action No. 3:20-cv-1634). On July 31, 2020, the Company filed a motion to dismiss the Western District of Texas case based improper venue. The parties are now conducting limited discovery related to this motion, after which Natera will file its responsive pleadings. The Northern District of Texas case has been stayed until a decision with respect to the motion to dismiss is made. On July 2, 2020, the Company filed a Complaint for Declaratory Judgment of Non-Infringement against Natera in the Southern District of California (S.D. California Civil Action No. 3:20-cv-1252). This case has been stayed pending the outcome of the Company’s venue motion in the Western District of Texas. Management believes that the claims in Natera’s complaints are without merit and the Company is vigorously defending against them. IPO Litigation On June 23, 2020, the Company completed the IPO. Subsequent to the IPO, two lawsuits were filed against the Company, certain of its executive officers and directors, and the underwriters of the IPO. The lawsuits allege that the Company’s registration statement and related prospectus for the IPO made false and misleading statements and omissions in violation of the Securities Act of 1933 by failing to disclose that the Company (i) had overbilled government payors by $10.3 million in 2019 and early 2020; (ii) would need to refund this overpayment in the second quarter of 2020; and (iii) were allegedly suffering from accelerating negative trends with respect to testing volumes, revenues, and product pricing during the second quarter of 2020. Both lawsuits seek, among other things, unspecified compensatory damages, interest, costs, and attorneys’ fees. The Company intends to vigorously defend against these claims. Given the uncertainty of litigation, the preliminary stages of these cases, and the legal standards that must be met for, among other things, success on the merits, the Company is unable to predict the ultimate outcome of these actions, and therefore cannot estimate the reasonably possible loss or range of loss, if any, that may result from these actions. Subject to a reservation of rights, the Company is advancing expenses subject to indemnification by the underwriters of the IPO. More details on each lawsuit are below: • Soe Action . On August 28, 2020, a putative securities class action was filed in the U.S. District Court for the Southern District of California, entitled , No. 3:20-cv-01683-CAB-AHG. The plaintiff, Aung Kyaw Soe, seeks to bring this action on behalf of all purchasers of Progenity common stock pursuant to or traceable to the registration statement issued in connection with the IPO. On September 23, 2020, the court ordered that no defendant has any obligation to answer or otherwise respond to the complaint in this action pending appointment of a lead plaintiff and the lead plaintiff’s filing of an amended complaint or designation of the existing complaint as the operative complaint. • Brickman Investments Inc. Action . On September 11, 2020, another putative securities class action was filed in the U.S. District Court for the Southern District of California, entitled , No. 3:20-cv-01795-BEN-LL. The plaintiff, Brickman Investments Inc., seeks to bring this action on behalf of all purchasers of Progenity common stock pursuant to or traceable to the registration statement and related prospectus issued in connection with the IPO. In addition to the remedies described above, the plaintiff seeks rescission or rescissory damages. Motions for appointment of lead plaintiff and lead counsel, as well as to consolidate the two actions, are pending.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders Equity Note [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Common Stock Pursuant to the Company’s eighth amended and restated certificate of incorporation, which went into effect immediately prior to the completion of the IPO, the Company is authorized to issue 350 million shares of common stock and 10 million shares of undesignated preferred stock On June 18, 2020, the Company completed its IPO. In the IPO, the Company issued and sold 6,666,667 shares of its common stock, at a price to the public of $15.00 per share. The Company received approximately $88.7 million in net proceeds, after deducting $ 7.0 in 4.3 in Treasury Stock In June 2014, the Company authorized an Equity Repurchase Program for Key Employees (the “Repurchase Program”). The Repurchase Program allowed the Company to repurchase for cash a portion of the common stock equity interests of certain employees, provided that (i) no more than 25% of the equity interest of any employee was repurchased under the Repurchase Program, (ii) the purchase price paid for each share of common stock equaled the most recent appraisal valuation of the Company’s common stock, and (iii) the aggregate repurchases did not exceed the lesser of (a) equity interest representing, in the aggregate, 0.8 million shares of common stock, (b) a purchase price, in the aggregate, of more than $6.0 million, and (c) the maximum repurchases permitted under the General Corporation Law of the State of Delaware. In addition, it was the Company’s practice to require individuals exercising stock options to hold the shares received upon exercising for a reasonable period of time in order for the holder to be exposed to the economic risks and rewards of share ownership prior to participating in the Repurchase Program. A reasonable period of time was defined as a period of at least six months and that covered at least two common stock appraisal valuations. The Repurchase Program has been discontinued. Convertible Preferred Stock As of December 31, 2019, the Company had outstanding Series A Preferred Stock and Series B Preferred Stock. The Company recorded the preferred stock at fair value on the dates of issuance net of issuance costs. On August 27, 2019, the Company issued 9,090,910 shares of Series B Preferred Stock at an issuance price of $2.75 per share for an aggregate consideration of $25.0 million (the “August 2019 Financing”) pursuant to a Series B Preferred Stock Purchase Agreement with a private equity firm. In addition, the Company amended the Series B Preferred Stock Purchase Warrant dated October 27, 2017 to increase the Series B Preferred Stock underlying the Series B Preferred Stock Purchase Warrant from 1,416,431 shares to 1,818,182 shares and adjust the exercise price to $2.75 per share. The $25.0 million of proceeds from the August 2019 Financing were allocated among the newly issued Series B Preferred Stock shares and additional shares of Series B Preferred Stock Purchase Warrant based on their relative fair values. In connection with the August 2019 Financing, the Board of Directors and stockholders approved a 1.28-for-1 stock split for the Company’s Series B Preferred Stock and Series B Preferred Stock Purchase Warrant issued and outstanding prior to the August 2019 Financing, which was effected on August 27, 2019 pursuant to an amendment to the amended and restated certificate of incorporation. The conversion price of the Series B Preferred Stock and exercise price of the outstanding Series B Preferred Stock Purchase Warrant was lowered from $3.53 to $2.75 per share. As a result, the Company issued 4,017,512 additional shares of Series B Preferred Stock as a stock dividend to the preferred stockholders, which was recorded as a $13.1 million increase to accumulated deficit in the consolidated statements of stockholders’ deficit during the year ended December 31, 2019. On August 27, 2019, the Company entered into an Exchange Agreement with holders of Series A-1 Preferred Stock (the “Exchange Agreement”) pursuant to which the outstanding 1,500,000 shares of Series A-1 Preferred Stock were exchanged for 35,664,240 shares of Series B Preferred Stock. The exchange ratio was 1.2 to 1 on as-if converted to 4,810,651 shares of common stock that the Series A-1 Preferred Stock can be converted to, based on the conversion rate of 3.2 to 1. The Company determined that such exchange constituted a modification to the Series A-1 Preferred Stock. Accordingly, the increase comparing the fair value of the Series B Preferred Stock with the fair value of the Series A-1 Preferred Stock represented a dividend to the preferred stockholders of approximately $27.6 million, which was recorded as an increase to accumulated deficit in the consolidated statements of stockholders’ deficit during the year ended December 31, 2019. On November 12, 2019, the Company entered into a Series B Preferred Stock Purchase Agreement (the “November Series B Preferred Stock Purchase Agreement”) with a private equity firm and received $25.0 million (the “November 2019 Financing”) in exchange for the issuance of 11,111,111 shares of Series B Preferred Stock at $2.25 per share. In connection with the November 2019 Financing, the Board of Directors and stockholders approved a 1.22-for-1 stock split for the Company’s Series B Preferred Stock and Series B Preferred Stock Purchase Warrant issued and outstanding prior to the November 2019 Financing. The conversion price of the Series B Preferred Stock and exercise price of the outstanding Series B Preferred Stock Purchase Warrant was lowered from $2.75 to $2.25 per share. As a result, the Company issued 13,985,993 additional shares of Series B Preferred Stock and adjusted the Series B Preferred Stock Purchase Warrant to purchase up to 2,222,222 shares of Series B Preferred Stock. The issuance of additional shares represented a stock dividend to the preferred stockholders, which was recorded as a $36.4 million increase to accumulated deficit in the consolidated statements of stockholders’ deficit during the year ended December 31, 2019. In connection with the November 2019 Financing, the Company amended the certificate of incorporation. Following the amendment, there are no authorized or outstanding shares of Series A-1 Preferred Stock. On November 22, 2019, the Company completed an additional equity financing pursuant to the November Series B Preferred Stock Purchase Agreement with certain existing, accredited investors for an aggregate of $6.1 million in exchange for the issuance of an aggregate of 2,722,222 shares of Series B Preferred Stock at $2.25 per share. On December 19, 2019, the Company completed an additional equity financing pursuant to the November Series B Preferred Stock Purchase Agreement with the same private equity firm as the November 2019 Financing for $25.0 million in exchange for the issuance of 11,111,111 shares of Series B Preferred Stock at $2.25 per share. In February 2020, the Company issued and sold an aggregate of 5,066,666 shares of Series B Preferred Stock at a purchase price of $2.25 per share to existing investors in exchange for aggregate consideration of approximately $11.4 million. On March 31, 2020, in connection with the Credit Agreement Amendment, which provided for the payment of interest due and payable as of March 31, 2020 and June 30, 2020 (only in the event the IPO had not been consummated by such date) in shares of Series B Preferred Stock, the Company issued an aggregate of 967,130 shares of Series B Preferred Stock at a subscription price of $2.25 per share to existing investors as payment for interest due and payable as of March 31, 2020 and all applicable fees. On April 3, 2020, the Company issued and sold an aggregate of 4,444,444 shares of its Series B Preferred Stock at a purchase price of $2.25 per share to existing investors in exchange for aggregate consideration of approximately $10.0 million in cash. The fair value of the preferred stock was estimated using a hybrid between a probability-weighted expected return method (“PWERM”) and option pricing model (“OPM”), estimating the probability weighted value across multiple scenarios, while using an OPM to estimate the allocation of value within one or more of these scenarios. Under a PWERM, the value of the Company’s various classes of stock was estimated based upon an analysis of future values for the Company assuming various future outcomes, including two IPO scenarios and one scenario contemplating the continued operation of the Company as a privately held enterprise. Guideline public company multiples were used to value the Company under its various scenarios. Share value for each class of stock was based upon the probability-weighted present value of expected future share values, considering each of these possible future outcomes, as well as the rights of each share class. The significant unobservable inputs into the valuation model used to estimate the fair value of the preferred stock include the timing of potential events (primarily the IPO) and their probability of occurring, the selection of guideline public company multiples, a discount for the lack of marketability of the common stock, and the discount rate used to calculate the present value of the estimated equity value allocated to each share class. Preferred stock outstanding as of December 31, 2019 consisted of the following (in thousands, except share and per share data): December 31, 2019 Shares Authorized Shares Issued and Outstanding Per Share Price at Issuance Aggregate Liquidation Preference Series A 4,120,000 4,120,000 $ 0.48543 $ 2,000 Series B 126,035,000 101,867,405 2.25000 229,202 Total preferred stock 130,155,000 105,987,405 $ 231,202 In connection with the IPO, on June 18, 2020, all outstanding Series A Preferred Stock and Series B Preferred Stock converted into 33,443,562 shares of common stock, including the issuance of 2,045,522 shares of common stock pursuant to an adjustment in the conversion rate of all of the shares of Series B Preferred Stock outstanding immediately prior to the IPO. Upon conversion of the convertible preferred stock, the Company reclassified their carrying value to common stock and additional paid-in capital. Common Stock Reserved for Future Issuance The Company reserved shares of common stock, on an as-if-converted basis, for future issuance as follows: September 30, 2020 December 31, 2019 Series A Preferred Stock — 13,213,254 Series B Preferred Stock — 16,488,731 Series B Preferred Stock Purchase Warrant — 359,699 Common stock warrant 400,160 — Restricted stock units outstanding 1,194,077 322,608 Outstanding options to purchase common stock 3,531,577 2,561,866 Available for future issuance under equity incentive plan 4,109,953 1,717,817 Total 9,235,767 34,663,975

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation In February 2018, the Company adopted the 2018 Equity Incentive Plan (the “2018 Plan”), with 0.7 million shares available for future grant. Upon adoption of the 2018 Plan, no new stock options or awards are issuable under the Second Amended and Restated 2012 Stock Plan (the “2012 Plan”) or the 2015 Consultant Stock Plan (the “2015 Plan”). The 2018 Plan is the successor to and continuation of the 2012 Plan, as amended, and the 2015 Plan, and is administered with either stock options or restricted stock units. The 2018 Plan also provides for other types of equity to issue awards, which at this time the Company does not plan to utilize. The 2018 Plan was amended in March 2019 with 1.1 million shares available for future grant. In December 2019, the Company adopted the Second Amended and Restated 2018 Equity Incentive Plan, which increased the number of shares available for future grant to 2.7 million shares. On March 4, 2020, the Board of Directors adopted the Third Amended and Restated 2018 Equity Incentive Plan (the “2018 Third Amended Plan”), which increased the number of shares available for future grant to a total of 7.6 million shares and was approved by stockholders on March 5, 2020. The Board of Directors administers the plans. In January 2020, the Board of Directors approved the modification of the exercise price of certain outstanding stock options under the existing incentive plans. As a result of this modification, an additional stock-based compensation expense of $0.9 million is being recognized over the remaining vesting period for the unvested stock options. Activity under the 2012 Plan, the 2015 Plan, and the 2018 Third Amended Plan for the nine months ended September 30, 2020, is set forth below (in thousands, except share and per share data): Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Balance at December 31, 2019 2,561,866 $ 9.01 Options granted 1,757,170 10.23 Options exercised (505,852 ) 1.14 Options forfeited/cancelled (281,607 ) 11.31 Balance at September 30, 2020 3,531,577 $ 9.01 7.67 $ 3,965 Vested and expected to vest at September 30, 2020 3,531,577 $ 9.01 7.64 $ 3,965 Vested and exercisable at September 30, 2020 1,674,215 $ 7.98 5.81 $ 3,744 As of September 30, 2020, the number of shares available for grant under the 2018 Third Amended Plan was 4,109,953. The Company uses the Black-Scholes option pricing model to estimate the fair value of each option grant on the date of grant or any other measurement date. The following table sets forth the assumptions used to determine the fair value of stock options granted during the nine months ended September 30, 2020: Nine Months Ended September 30, 2020 Risk-free interest rate 0.4% - 1.7% Expected volatility 57.0% - 71.0% Expected dividend yield — Expected life (years) 4.0 - 6.3 years The following table presents total stock-based compensation expense included in each functional line item in the accompanying condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of sales $ 311 $ 59 $ 749 $ 161 Research and development 815 216 2,327 598 Selling and marketing 444 128 1,329 379 General and administrative 1,804 228 4,050 645 Total stock-based compensation expense $ 3,374 $ 631 $ 8,455 $ 1,783 The weighted-average grant date fair value of options granted during the nine months ended September 30, 2020 and 2019 was $6.51 per option and $7.42 per option, respectively. At September 30, 2020 and December 31, 2019, there was $12.2 million and $4.1 million, respectively, of compensation cost related to unvested stock options expected to be recognized over a remaining weighted average vesting period of 3.01 years and 2.69 years, respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The Company calculates its interim income tax provision in accordance with ASC Topic 270, Interim Reporting Accounting for Income Taxes On March 27, 2020, the CARES Act was enacted. The CARES Act includes several significant provisions for corporations, including those pertaining to net operating loss (“NOL”) carryforwards, interest deductions and payroll tax benefits. Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years. During the first quarter of 2020, the Company recorded a discrete tax benefit of $37.7 million related to the NOL carryback provisions available under the CARES Act legislation corresponding to anticipated tax refunds applicable to taxable years 2013, 2014, 2015, and 2017. If any tax refund is received that is more than $5.0 million in a single year, along with other civil settlements, damages awards, and tax refunds, the Company has agreed to pay 65% of all such amounts received to accelerate payments to the government in connection with the government settlement (see Note 9). During the nine months ended September 30, 2020, the Company received a tax refund of $38.4 million related to the NOL carryback provisions available under the CARES Act, including $15.7 million tax refund in the third quarter of 2020 related to the 2019 NOL. The Company’s NOL carryforwards and research and expenditure credit carryforwards may be subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”), and similar state provisions if the Company experiences an ownership change within the meaning of such Code sections. In general, an ownership change, as defined by Sections 382 and 383 of the Code, occurs when there is a 50 percentage points or more shift in ownership, consisting of shareholders owning more than 5% in the Company, occurring within a three-year testing period. During the third quarter 2020, the Company completed a formal Section 382 study and concluded that an ownership change, within the meaning of Sections 382 and 383, limiting future utilization of existing tax attribute carry-forwards, had not occurred.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share Net loss per share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options, as well as from the possible conversion of the Company’s preferred stock and exercise of the outstanding warrant. The treasury stock and if-converted methods are used to calculate the potential dilutive effect of these common stock equivalents. However, potentially dilutive shares are excluded from the computation of diluted loss per share when their effect is antidilutive. Due to the Company reporting a net loss attributable to common stockholders for all periods presented, all potentially dilutive securities were antidilutive and have been excluded from the computation of diluted loss per share. The table below provides potentially dilutive securities in equivalent common shares not included in the Company’s calculation of diluted loss per share because to do so would be antidilutive: September 30, 2020 September 30, 2019 Options to purchase common stock 3,531,577 2,571,297 Restricted stock units 1,194,077 316,481 Common stock warrant 400,160 — Series A Preferred Stock — 13,213,254 Series B Preferred Stock — 10,187,272 Series B Preferred Stock Purchase Warrant — 294,299 Total 5,125,814 26,582,603

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) fo r interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. he Company’s final prospectus filed with the Securities and Exchange Commission on June 22, 2020
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying condensed consolidated balance sheet as of September 30, 2020, the statements of operations and the statements of stockholders’ deficit for the three and nine months ended September 30, 2020 and 2019 and the statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, that are necessary for the fair statement of the Company’s financial position as of September 30, 2020, and the results of its operations and its cash flows for the three and nine months ended September 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2020 and 2019 are also unaudited. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period, particularly in light of the COVID-19 pandemic and its impact on domestic and global economies
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include the estimate of variable consideration in connection with the recognition of revenue, the valuation of Series B preferred stock, the valuation of stock options, the valuation of goodwill and intangible assets, accrual for reimbursement claims and settlements, assessing future tax exposure and the realization of deferred tax assets, the useful lives and the recoverability of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.
Operating Segments	Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. All revenues are attributable to U.S.-based operations and all assets are held in the United States.
Revenue Recognition	Revenue Recognition Revenue is recognized in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Revenue is primarily derived from providing molecular testing products, which are reimbursed through arrangements with third-party payors, laboratory distribution partners, and amounts from individual patients. Third-party payors include commercial payors, such as health insurance companies, health maintenance organizations and government health benefit programs, such as Medicare and Medicaid. The Company’s contracts generally contain a single performance obligation, which is the delivery of the test results, and the Company satisfies its performance obligation at a point in time upon the delivery of the results, which then triggers the billing for the product. The amount of revenue recognized reflects the amount of consideration the Company expects to be entitled to (the “transaction price”) and considers the effects of variable consideration. Revenue is recognized when control of the promised product is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products. The Company applies the following practical expedients and exemptions: • Incremental costs incurred to obtain a contract are expensed as incurred because the related amortization period would have been one year or less. The costs are included in selling and marketing expenses. • No adjustments to amounts of promised consideration are made for the effects of a significant financing component because the Company expects, at contract inception, that the period between the transfer of a promised good or service and customer payment for that good or service will be one year or less.
Payor Concentration	Payor Concentration The Company relies upon reimbursements from third-party government payors and private-payor insurance companies to collect accounts receivable. The Company’s significant third-party payors and their related accounts receivable balances and revenues as a percentage of total accounts receivable balances and revenues are as follows: Percentage of Accounts Receivable September 30, 2020 December 31, 2019 Blue Shield of Texas 21.4 % 0.1 % Government Health Benefits Programs 20.5 % 16.7 % Aetna 6.4 % 6.0 % United Healthcare 5.7 % 31.5 % Percentage of Revenue Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Blue Shield of Texas 26.5 % 47.2 % 35.4 % 19.4 % Government Health Benefits Programs(1) 21.9 % (29.4 )% (5.6 )% 9.3 % Aetna 7.9 % 10.7 % 10.7 % 8.1 % United Healthcare 5.5 % 28.8 % 4.9 % 30.9 % ____________ (1) The negative amounts presented in the percentage of revenues include accruals for reimbursement claims and settlements included in the estimates of variable consideration recorded during the three and nine months ended September 30, 2020 and 2019. Revenue recognized consider the effects of variable consideration, and include adjustments for estimates of disallowed cases, discounts, and refunds. The variable consideration includes reductions in revenues for the accrual for reimbursement claims and settlements, as described in Notes 4 and 9.
Accounts Receivable	Accounts Receivable Accounts receivable is recorded at the transaction price and considers the effects of variable consideration. The total consideration the Company expects to collect is an estimate and may be fixed or variable. Variable consideration includes reimbursement from third-party payors, laboratory distribution partners, and amounts from individual patients, and is adjusted for disallowed cases, discounts, and refunds using the expected value approach. The Company monitors these estimates at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required.
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The Company considers all series of preferred stock to be participating securities as the holders of such stock are entitled to receive non-cumulative dividends on an as-converted basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stockholders is not allocated to the preferred stock as the holders of preferred stock do not have a contractual obligation to share in the Company’s losses. Under the two-class method, net income is attributed to common stockholders and participating securities based on their participation rights. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net loss attributable to common stockholders is calculated by adjusting net loss with dividends to preferred stockholders, if any. As the Company has reported net losses for all periods presented, all potentially dilutive securities are antidilutive and, accordingly, basic net loss per share equals diluted net loss per share.
Comprehensive Loss	Comprehensive Loss The Company did not have any other comprehensive income or loss for any of the periods presented, and therefore comprehensive loss was the same as the Company’s net loss.
Recent Accounting Pronouncements Adopted	Recent Accounting Pronouncements Adopted In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Accounting for Income Taxes
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Leases (Topic 840) Leases (Topic 842): Effective Dates The Company plans to adopt the new lease standard effective January 1, 2021, using the effective date method with the cumulative effect of the change reflected in retained earnings as of January 1, 2021, if any. The Company plans to elect the package of practical expedients available in the new lease standard, allowing it not to reassess: (a) whether expired or existing contracts contain leases under the new definition of a lease; (b) lease classification for expired or existing leases; and (c) whether previously capitalized initial direct costs would qualify for capitalization under the new lease standard. The Company continues to monitor FASB activity to assess certain interpretative issues and the associated implementation of the new standard and is in the process of reviewing its lease arrangements, including property, equipment and vehicle leases. The Company is not yet able to estimate the anticipated impact to its consolidated financial statements from the implementation of the new standard as it continues to interpret the principles of the new standard. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses Codification Improvements to Topic 326, Financing Instruments–Credit Losses In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of Accounts Receivable Balances and Revenues as Percentage of Total Accounts Receivable Balances and Revenues	The Company’s significant third-party payors and their related accounts receivable balances and revenues as a percentage of total accounts receivable balances and revenues are as follows: Percentage of Accounts Receivable September 30, 2020 December 31, 2019 Blue Shield of Texas 21.4 % 0.1 % Government Health Benefits Programs 20.5 % 16.7 % Aetna 6.4 % 6.0 % United Healthcare 5.7 % 31.5 % Percentage of Revenue Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Blue Shield of Texas 26.5 % 47.2 % 35.4 % 19.4 % Government Health Benefits Programs(1) 21.9 % (29.4 )% (5.6 )% 9.3 % Aetna 7.9 % 10.7 % 10.7 % 8.1 % United Healthcare 5.5 % 28.8 % 4.9 % 30.9 % ____________ (1) The negative amounts presented in the percentage of revenues include accruals for reimbursement claims and settlements included in the estimates of variable consideration recorded during the three and nine months ended September 30, 2020 and 2019. Revenue recognized consider the effects of variable consideration, and include adjustments for estimates of disallowed cases, discounts, and refunds. The variable consideration includes reductions in revenues for the accrual for reimbursement claims and settlements, as described in Notes 4 and 9.

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	9 Months Ended
	Sep. 30, 2020
Text Block [Abstract]
Schedule of Assets and Liabilities	The following table presents the assets and liabilities of Avero that are included in the Company’s condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, in thousands. The creditors of Avero have no recourse to the general credit of the Company, with the exception of $1.8 million and $1.9 million in mortgage payable guaranteed by the Company as of September 30, 2020 and December 31, 2019, respectively (see Note 8), and $0.8 million and $3.0 million in remaining Cigna settlement obligation guaranteed by the Company as of September 30, 2020 and December 31, 2019, respectively. The assets and liabilities exclude intercompany balances that eliminate in consolidation: September 30, 2020 December 31, 2019 Assets of Avero that can only be used to settle obligations of Avero Cash and cash equivalents $ 1,038 $ 1,837 Accounts receivable, net 4,733 4,269 Inventory 2,143 2,572 Prepaid expenses and other current assets 1,093 1,181 Property and equipment, net 5,486 5,586 Other assets 30 30 Goodwill 6,219 6,219 Other intangible assets, net 4,075 4,771 Total assets of Avero that can only be used to settle obligations of Avero $ 24,817 $ 26,465 Liabilities of Avero Accounts payable $ 3,166 $ 2,450 Accrued expenses and other accrued liabilities 3,609 5,630 Current portion of capital lease obligations 49 59 Current portion of mortgage payable 197 173 Capital lease obligations, net of current portion 16 50 Mortgage payable, net of current portion 1,570 1,733 Other long-term liabilities 571 467 Total liabilities of Avero $ 9,178 $ 10,562

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenues by Payor	The following table shows a further disaggregation of revenues by payor type (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Commercial third-party payors $ 18,555 $ 23,058 $ 58,148 $ 108,851 Government health benefit programs(1) 5,692 (5,513 ) (3,374 ) 11,432 Patient/laboratory distribution partners 1,696 1,227 5,263 3,226 Total revenues $ 25,943 $ 18,772 $ 60,037 $ 123,509 ____________ (1) The revenue amounts include accruals for reimbursement claims and settlements included in the estimates of variable consideration recorded during the three and nine months ended September 30, 2020 and 2019. Revenue recognized reflect the effects of variable consideration, and include adjustments for estimates of disallowed cases, discounts, and refunds. The variable consideration includes reductions in revenues for the accrual for reimbursement claims and settlements.

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): September 30, 2020 December 31, 2019 Prepaid expenses $ 8,188 $ 6,476 Other current assets 1,028 1,370 Total $ 9,216 $ 7,846
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): September 30, 2020 December 31, 2019 Computers and software $ 13,790 $ 13,913 Building and leasehold improvements 9,458 9,491 Laboratory equipment 7,254 5,580 Furniture, fixtures, and office equipment 1,686 1,633 Construction in progress 1,891 1,493 Land 1,091 1,091 Total property and equipment 35,170 33,201 Less accumulated depreciation and amortization (19,082 ) (17,310 ) Property and equipment, net $ 16,088 $ 15,891
Summary of Capital Leases Included in Property and Equipment, Net	Capital leases included in property and equipment, net consisted of the following (in thousands): September 30, 2020 December 31, 2019 Capital leases $ 2,467 $ 3,692 Less accumulated depreciation and amortization (1,835 ) (2,239 ) Capital leases included in property and equipment, net $ 632 $ 1,453
Summary of Intangible Assets, Net	Intangible assets, net consisted of the following (in thousands): September 30, 2020 Cost Accumulated amortization Net Payor relationships $ 7,230 $ (3,856 ) $ 3,374 Trade names 1,410 (752 ) 658 Noncompete agreements 384 (341 ) 43 Intangible assets, net $ 9,024 $ (4,949 ) $ 4,075 December 31, 2019 Cost Accumulated amortization Net Payor relationships $ 7,230 $ (3,314 ) $ 3,916 Trade names 1,410 (646 ) 764 Noncompete agreements 384 (293 ) 91 Intangible assets, net $ 9,024 $ (4,253 ) $ 4,771
Summary of Future Amortization of Intangible Assets	The future amortization of intangible assets at September 30, 2020 was (in thousands): Year ending December 31, Remainder of 2020 $ 232 2021 891 2022 864 2023 864 2024 864 Thereafter 360 Total future minimum lease payments $ 4,075
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accrual for reimbursement claims and settlements, current $ 47,937 $ 60,386 Commission and bonus 8,283 6,357 Vacation and payroll benefits 7,339 5,506 Accrued professional services 3,092 5,322 Contract liabilities 544 — Other 3,818 6,044 Total $ 71,013 $ 83,615
Summary of Other Long-term Liabilities	Other long-term liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accrual for reimbursement claims and settlements, net of current portion $ 18,066 $ 12,205 Other 2,022 654 Total $ 20,088 $ 12,859

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value (in thousands): Quoted Prices for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2020 Money market funds(1) $ 39,737 $ — $ — December 31, 2019 Money market funds(1) $ 24,432 $ — $ — ____________ (1) Included in cash and cash equivalents in the accompanying condensed consolidated balance sheets.

Mortgages Payable (Tables)

Mortgages Payable (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Minimum Principal Payments	As of September 30, 2020, the minimum principal payments under the mortgages payable were as follows (in thousands): Year ending December 31, Minimum Mortgages Payable Payments Obligations Remainder of 2020 $ 66 2021 271 2022 281 2023 292 2024 1,338 Thereafter 884 Total future minimum payments 3,132 Less current portion of mortgages payable (268 ) Mortgages payable, net of current portion $ 2,864

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Schedule of Net Minimum Payments Under Non-Cancelable Operating Leases	As of September 30, 2020, net minimum payments under the non-cancelable operating leases were as follows (in thousands): Year ending December 31, Minimum Operating Lease Payments Remainder of 2020 $ 1,933 2021 5,476 2022 3,017 2023 1,036 2024 and thereafter 38 Total future minimum lease payments $ 11,500
Schedule of Future Minimum Payments Under Capital Leases	As of September 30, 2020, the future minimum payments under the capital leases were as follows (in thousands): Year ending December 31, Minimum Capital Lease Payments Remainder of 2020 $ 145 2021 324 2022 and thereafter 47 Total future minimum lease payments 516 Less amounts representing interest (20 ) Present value of minimum capital lease payments 496 Less current portion of capital lease obligations (399 ) Capital lease obligations, net of current portion $ 97

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Stockholders Equity Note [Abstract]
Schedule of Preferred Stock Shares Authorized, Shares Issued and Outstanding, Per Share Price and Liquidation Preference	Preferred stock outstanding as of December 31, 2019 consisted of the following (in thousands, except share and per share data): December 31, 2019 Shares Authorized Shares Issued and Outstanding Per Share Price at Issuance Aggregate Liquidation Preference Series A 4,120,000 4,120,000 $ 0.48543 $ 2,000 Series B 126,035,000 101,867,405 2.25000 229,202 Total preferred stock 130,155,000 105,987,405 $ 231,202
Schedule of Reserved Shares of Common Stock, On An As-if-converted Basis, for Future Issuance	The Company reserved shares of common stock, on an as-if-converted basis, for future issuance as follows: September 30, 2020 December 31, 2019 Series A Preferred Stock — 13,213,254 Series B Preferred Stock — 16,488,731 Series B Preferred Stock Purchase Warrant — 359,699 Common stock warrant 400,160 — Restricted stock units outstanding 1,194,077 322,608 Outstanding options to purchase common stock 3,531,577 2,561,866 Available for future issuance under equity incentive plan 4,109,953 1,717,817 Total 9,235,767 34,663,975

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Options Activity under Plans	Activity under the 2012 Plan, the 2015 Plan, and the 2018 Third Amended Plan for the nine months ended September 30, 2020, is set forth below (in thousands, except share and per share data): Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Balance at December 31, 2019 2,561,866 $ 9.01 Options granted 1,757,170 10.23 Options exercised (505,852 ) 1.14 Options forfeited/cancelled (281,607 ) 11.31 Balance at September 30, 2020 3,531,577 $ 9.01 7.67 $ 3,965 Vested and expected to vest at September 30, 2020 3,531,577 $ 9.01 7.64 $ 3,965 Vested and exercisable at September 30, 2020 1,674,215 $ 7.98 5.81 $ 3,744
Summary of Assumptions used to Determine Fair Value of Stock Options Granted	The following table sets forth the assumptions used to determine the fair value of stock options granted during the nine months ended September 30, 2020: Nine Months Ended September 30, 2020 Risk-free interest rate 0.4% - 1.7% Expected volatility 57.0% - 71.0% Expected dividend yield — Expected life (years) 4.0 - 6.3 years
Schedule of Stock-based Compensation Expense	The following table presents total stock-based compensation expense included in each functional line item in the accompanying condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of sales $ 311 $ 59 $ 749 $ 161 Research and development 815 216 2,327 598 Selling and marketing 444 128 1,329 379 General and administrative 1,804 228 4,050 645 Total stock-based compensation expense $ 3,374 $ 631 $ 8,455 $ 1,783

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Summary of Potentially Dilutive Securities Not Included in Calculation of Diluted Loss Per Share	The table below provides potentially dilutive securities in equivalent common shares not included in the Company’s calculation of diluted loss per share because to do so would be antidilutive: September 30, 2020 September 30, 2019 Options to purchase common stock 3,531,577 2,571,297 Restricted stock units 1,194,077 316,481 Common stock warrant 400,160 — Series A Preferred Stock — 13,213,254 Series B Preferred Stock — 10,187,272 Series B Preferred Stock Purchase Warrant — 294,299 Total 5,125,814 26,582,603

Organization and Description _2

Organization and Description of Business - Additional Information (Details) $ / shares in Units, $ in Thousands	Jun. 23, 2020USD ($)$ / sharesshares	Jun. 18, 2020USD ($)$ / sharesshares	Jun. 10, 2020	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Description of stock split										On June 10, 2020, the Company amended its certificate of incorporation to reflect a one-for-6.178 reverse stock split of the Company’s common stock.
Stock split conversion ratio			0.162
Proceeds from issuance of common stock, net										$ 90,344	$ 530
Cash and cash equivalents				$ 60,013						60,013		$ 33,042
Accumulated deficit				(465,746)						(465,746)		$ (348,478)
Net loss				(47,065)	$ (52,783)	$ (17,152)	$ (57,133)	$ (16,409)	$ (24,019)	(117,000)	(97,561)
Cash used in operating activities										(95,687)	$ (60,279)
Mortgages
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Outstanding balance				3,100						3,100
Private Equity Firm | 2017 Term Loan
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Outstanding balance				$ 75,000						$ 75,000
IPO | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock issued and sold | shares	6,666,667	6,666,667
Share issued price per share | $ / shares	$ 15	$ 15
Proceeds from issuance of common stock, net	$ 88,700	$ 88,700

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - Segment	9 Months Ended
	Sep. 30, 2020	Mar. 31, 2020
Summary Of Significant Accounting Policies [Line Items]
Number of operating segment	1
Accounting Standards Update 2018-07
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Accounting Standards Update 2019-12
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true
Change in accounting principle, accounting standards update, immaterial effect [true false]		true
Change in accounting principle, accounting standards update, early adoption [true false]		true
Accounting Standards Update 2016-02
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	false
Accounting Standards Update 2016-13
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	false
Accounting Standards Update 2017-04
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	false
Maximum
Summary Of Significant Accounting Policies [Line Items]
Amortization period	1 year

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Accounts Receivable Balances and Revenues as Percentage of Total Accounts Receivable Balances and Revenues (Details) - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Blue Shield of Texas | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable			21.40%		0.10%
Blue Shield of Texas | Revenue
Concentration Risk [Line Items]
Percentage of revenues	26.50%	47.20%	35.40%	19.40%
Government Health Benefits Programs | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable			20.50%		16.70%
Government Health Benefits Programs | Revenue
Concentration Risk [Line Items]
Percentage of revenues	21.90%	(29.40%)	(5.60%)	9.30%
Aetna | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable			6.40%		6.00%
Aetna | Revenue
Concentration Risk [Line Items]
Percentage of revenues	7.90%	10.70%	10.70%	8.10%
United Healthcare | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable			5.70%		31.50%
United Healthcare | Revenue
Concentration Risk [Line Items]
Percentage of revenues	5.50%	28.80%	4.90%	30.90%

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2015	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 05, 2018
Variable Interest Entity [Line Items]
Liabilities		$ 180,037,000		$ 180,037,000			$ 185,601,000
Remaining settlement obligation of mortgage loan		800,000		800,000			3,000,000
Cigna Settlement Obligation
Variable Interest Entity [Line Items]
Settlement of obligations guaranteed						$ 12,000,000
Avero
Variable Interest Entity [Line Items]
Term of agreement	10 years
Financial support for obligation settlement		800,000		2,300,000
Liabilities		9,178,000		9,178,000			10,562,000
Mortgage payable		1,800,000		1,800,000			1,900,000
Avero | Recourse
Variable Interest Entity [Line Items]
Liabilities		$ 0		$ 0			$ 0
Avero | Cigna Settlement Obligation
Variable Interest Entity [Line Items]
Litigation settlement amount agreed to pay to other party								$ 12,000,000
Litigation settlement upfront payment								6,000,000
Remaining settlement amount								$ 6,000,000
Financial support for obligation settlement			$ 800,000		$ 2,300,000

Variable Interest Entities - Sc

Variable Interest Entities - Schedule of Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents	$ 60,013	$ 33,042
Accounts receivable, net	13,425	22,189
Inventory	10,383	10,937
Prepaid expenses and other current assets	9,216	7,846
Property and equipment, net	16,088	15,891
Other assets	198	198
Goodwill	6,219	6,219
Other intangible assets, net	4,075	4,771
Total assets	119,617	101,727
Liabilities of Avero
Accounts payable	15,666	15,754
Current portion of capital lease obligations	399	727
Current portion of mortgages payable	268	241
Capital lease obligations, net of current portion	97	358
Mortgages payable, net of current portion	2,864	3,081
Other long-term liabilities	20,088	12,859
Total liabilities	180,037	185,601
Avero
Assets
Cash and cash equivalents	1,038	1,837
Accounts receivable, net	4,733	4,269
Inventory	2,143	2,572
Prepaid expenses and other current assets	1,093	1,181
Property and equipment, net	5,486	5,586
Other assets	30	30
Goodwill	6,219	6,219
Other intangible assets, net	4,075	4,771
Total assets	24,817	26,465
Liabilities of Avero
Accounts payable	3,166	2,450
Accrued expenses and other accrued liabilities	3,609	5,630
Current portion of capital lease obligations	49	59
Current portion of mortgages payable	197	173
Capital lease obligations, net of current portion	16	50
Mortgages payable, net of current portion	1,570	1,733
Other long-term liabilities	571	467
Total liabilities	$ 9,178	$ 10,562

Revenues - Additional Informati

Revenues - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Amount of reimbursement overpayment received from government payors		$ 10.3
Accrued refunds to government payors	$ 10.3			$ 10.3
Performance obligations resulted in increase (decrease) of revenue	$ 3.3		$ (17.8)	$ (19.4)	$ 1

Revenues - Summary of Disaggreg

Revenues - Summary of Disaggregation of Revenues by Payor (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Total revenues	$ 25,943	$ 18,772	$ 60,037	$ 123,509
Commercial Third-party Payors
Disaggregation Of Revenue [Line Items]
Total revenues	18,555	23,058	58,148	108,851
Government Health Benefit Programs
Disaggregation Of Revenue [Line Items]
Total revenues	5,692	(5,513)	(3,374)	11,432
Patient/Laboratory Distribution Partners
Disaggregation Of Revenue [Line Items]
Total revenues	$ 1,696	$ 1,227	$ 5,263	$ 3,226

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Prepaid expenses	$ 8,188	$ 6,476
Other current assets	1,028	1,370
Total	$ 9,216	$ 7,846

Balance Sheet Components - Su_2

Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Total property and equipment	$ 35,170	$ 33,201
Less accumulated depreciation and amortization	(19,082)	(17,310)
Property and equipment, net	16,088	15,891
Computers and Software [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	13,790	13,913
Building and Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	9,458	9,491
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	7,254	5,580
Furniture, Fixtures, and Office Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	1,686	1,633
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	1,891	1,493
Land [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	$ 1,091	$ 1,091

Balance Sheet Components - Su_3

Balance Sheet Components - Summary of Capital Leases Included in Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Capital leases	$ 2,467	$ 3,692
Less accumulated depreciation and amortization	(1,835)	(2,239)
Capital leases included in property and equipment, net	$ 632	$ 1,453

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Depreciation expense	$ 1	$ 0.9	$ 3.1	$ 2.8
Amortization expense of intangible assets	$ 0.2	$ 0.7	$ 0.2	$ 0.7

Balance Sheet Components - Su_4

Balance Sheet Components - Summary of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Cost	$ 9,024	$ 9,024
Accumulated amortization	(4,949)	(4,253)
Net	4,075	4,771
Payor Relationships [Member]
Finite Lived Intangible Assets [Line Items]
Cost	7,230	7,230
Accumulated amortization	(3,856)	(3,314)
Net	3,374	3,916
Trade Names [Member]
Finite Lived Intangible Assets [Line Items]
Cost	1,410	1,410
Accumulated amortization	(752)	(646)
Net	658	764
Noncompete Agreements [Member]
Finite Lived Intangible Assets [Line Items]
Cost	384	384
Accumulated amortization	(341)	(293)
Net	$ 43	$ 91

Balance Sheet Components - Su_5

Balance Sheet Components - Summary of Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Remainder of 2020	$ 232
2021	891
2022	864
2023	864
2024	864
Thereafter	360
Net	$ 4,075	$ 4,771

Balance Sheet Components - Su_6

Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accrual for reimbursement claims and settlements, current	$ 47,937	$ 60,386
Commission and bonus	8,283	6,357
Vacation and payroll benefits	7,339	5,506
Accrued professional services	3,092	5,322
Contract liabilities	544
Other	3,818	6,044
Total	$ 71,013	$ 83,615

Balance Sheet Components - Su_7

Balance Sheet Components - Summary of Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accrual for reimbursement claims and settlements, net of current portion	$ 18,066	$ 12,205
Other	2,022	654
Total	$ 20,088	$ 12,859

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value on Recurring Basis | Quoted Prices for Identical Assets (Level 1) | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets at fair value	$ 39,737	$ 24,432

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer of assets from level 1 to level 2	$ 0		$ 0
Transfer of assets from level 2 to level 1	0		$ 0
2017 Term Loan
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Carrying value of term loan	75,000,000	$ 75,000,000
Fair value of term loan	$ 80,000,000	$ 79,800,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	May 08, 2020	Oct. 27, 2017	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 18, 2020	Apr. 03, 2020	Mar. 31, 2020	Feb. 29, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Debt discount amortization							$ 1,902,000	$ 1,229,000
Unamortized discount					$ 5,358,000		5,358,000						$ 6,034,000
Interest expense					2,476,000	$ 2,321,000	7,285,000	6,872,000
Change in fair value of derivative liability							(126,000)
Loss on extinguishment of debt							3,401,000
Unsecured Convertible Promissory Note
Related Party Transaction [Line Items]
Debt instrument, maturity date	May 8, 2022
Loan amount	$ 15,000,000
Debt discount amortization			$ 200,000
Debt instrument, annual interest rate	8.00%
Conversion price percentage on IPO price	80.00%
Percentage of premium on aggregate principal amount	50.00%
Derivative liability, fair value	$ 3,600,000				$ 3,800,000		$ 3,800,000
Fair value of common shares issued			3,400,000
Unsecured Convertible Promissory Note | Interest and Other Income (Expense), Net
Related Party Transaction [Line Items]
Change in fair value of derivative liability				$ 200,000
Loss on extinguishment of debt			$ 3,600,000
IPO | Unsecured Convertible Promissory Note
Related Party Transaction [Line Items]
Number of shares on debt conversion			1,250,000
Series B Preferred Stock
Related Party Transaction [Line Items]
Preferred stock, shares issued					0		0			4,444,444		5,066,666	101,867,405
Shares issued, price per share												$ 2.25
Series B Preferred Stock | Unsecured Convertible Promissory Note
Related Party Transaction [Line Items]
Convertible conversion price	$ 13.90
Percentage of price per share	80.00%
Series B Preferred Stock Purchase Warrant | Common Stock | IPO
Related Party Transaction [Line Items]
Warrants exercisable									400,160
2017 Term Loan
Related Party Transaction [Line Items]
Term loan					$ 75,000,000		$ 75,000,000						$ 75,000,000
Credit and Security Agreement and Series B Convertible Preferred Stock Purchase Agreement with Private Equity Firm
Related Party Transaction [Line Items]
Loan amount		$ 75,000,000
Debt discount amortization		$ 9,300,000
Credit and Security Agreement and Series B Convertible Preferred Stock Purchase Agreement with Private Equity Firm | 2017 Term Loan
Related Party Transaction [Line Items]
Debt instrument, interest rate per annum		9.50%
Debt instrument, maturity date							Oct. 27, 2022
Debt instrument, covenant description							The 2017 Term Loan contains customary covenants, including a requirement to maintain a minimum unrestricted cash balance at all times of at least $5.0 million. The Company is in compliance with the 2017 Term Loan covenants. The 2017 Term Loan is secured by all tangible and intangible property and assets of the Company, with the exception of its intellectual property.
Proceeds from term loan		$ 65,700,000
Debt discount amortization					600,000	400,000	$ 1,700,000	1,200,000
Term loan					75,000,000		75,000,000						75,000,000
Unamortized discount					5,400,000		5,400,000						$ 6,000,000
Interest expense					$ 2,400,000	$ 2,200,000	$ 7,100,000	$ 6,600,000
Credit and Security Agreement and Series B Convertible Preferred Stock Purchase Agreement with Private Equity Firm | 2017 Term Loan | Series B Preferred Stock
Related Party Transaction [Line Items]
Proceeds from term loan, preferred stock and preferred stock purchase warrant		124,200,000
Credit and Security Agreement and Series B Convertible Preferred Stock Purchase Agreement with Private Equity Firm | 2017 Term Loan | Minimum
Related Party Transaction [Line Items]
Unrestricted cash		$ 5,000,000
Subscription Agreement with Lender | Series B Preferred Stock
Related Party Transaction [Line Items]
Preferred stock, shares issued											967,130
Shares issued, price per share											$ 2.25

Mortgages Payable - Additional

Mortgages Payable - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Jan. 31, 2014
Comerica Bank
Debt Instrument [Line Items]
Mortgages Payable			$ 1.8
Outstanding balance	$ 1.4	$ 1.4
Mortgage maturity year	2024
Comerica Bank | LIBOR
Debt Instrument [Line Items]
Interest rate	2.94%
American Bank of Commerce
Debt Instrument [Line Items]
Outstanding balance	$ 1.8	$ 1.9
Interest rate	3.25%
Mortgage maturity year	2029

Mortgages Payable - Schedule of

Mortgages Payable - Schedule of Minimum Principal Payments (Details) - Mortgages $ in Thousands	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Remainder of 2020	$ 66
2021	271
2022	281
2023	292
2024	1,338
Thereafter	884
Total future minimum payments	3,132
Less current portion of mortgages payable	(268)
Mortgages payable, net of current portion	$ 2,864

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)

Jul. 23, 2020USD ($)

Jul. 21, 2020USD ($)State

Jun. 30, 2020USD ($)

Sep. 30, 2020USD ($)

Jun. 30, 2020USD ($)

Mar. 31, 2020USD ($)

Sep. 30, 2019USD ($)

Sep. 30, 2020USD ($)Case

Sep. 30, 2019USD ($)

Dec. 31, 2018USD ($)

Oct. 02, 2020USD ($)

Oct. 01, 2020USD ($)

Dec. 31, 2019USD ($)

Dec. 05, 2018USD ($)

Oct. 18, 2018USD ($)

Jun. 25, 2018USD ($)

Commitment and Contingencies [Line Items]

Rent expense for operating leases

$ 1,800,000

$ 2,300,000

$ 6,000,000

$ 6,600,000

Weighted average imputed interest rate

5.98%

5.98%

Number of states participating in settlement | State

45

Contractual obligation

$ 13,200,000

$ 13,200,000

Contractual obligation in December 2022

$ 1,100,000

Income taxes percentage of payments related to civil settlement damages awards and tax refund, CARES Act

65.00%

Income tax discrete benefit related to net operating loss, CARES Act

$ 37,700,000

Contractual obligation tax benefits

$ 38,400,000

Percentage of contractual obligation initial payments

1700000000.00%

1700000000.00%

Contractual obligation in December 2021

1,400,000

Contractual obligation in December 2022

1,900,000

Contractual obligation in December 2023

200,000

Accrual settlement amount

13,200,000

$ 35,800,000

Amount of reimbursement overpayment received from government payors

$ 10,300,000

Number of actions pending | Case

2

Accrued Expenses And Other Current Liabilities

Commitment and Contingencies [Line Items]

Remaining accrual balance

$ 20,200,000

$ 20,200,000

Other Long Term Liabilities

Commitment and Contingencies [Line Items]

Remaining accrual balance

12,100,000

$ 12,100,000

Subsequent Event

Commitment and Contingencies [Line Items]

Contractual obligation

$ 8,700,000

Cigna Settlement Obligation | Avero

Commitment and Contingencies [Line Items]

Litigation settlement agreement date

December 5, 2018

Litigation settlement amount agreed to pay to other party

$ 12,000,000

Litigation settlement upfront payment

6,000,000

Remaining settlement amount

$ 6,000,000

Litigation settlement reduction of revenue

$ 12,000,000

Cigna Settlement Obligation | Accrued Expenses And Other Current Liabilities | Avero

Commitment and Contingencies [Line Items]

Remaining accrual balance

800,000

$ 800,000

Aetna Settlement Agreement

Commitment and Contingencies [Line Items]

Litigation settlement agreement date

November 2019

Litigation settlement amount agreed to pay to other party

$ 15,000,000

Litigation settlement reduction of revenue

$ 15,000,000

Aetna Settlement Agreement | Accrued Expenses And Other Current Liabilities

Commitment and Contingencies [Line Items]

Remaining accrual balance

5,000,000

$ 5,000,000

United Health Group Settlement Agreement

Commitment and Contingencies [Line Items]

Remaining accrual balance

18,000,000

$ 18,000,000

Litigation settlement agreement date

September 30, 2019

Litigation settlement amount agreed to pay to other party

$ 30,000,000

Litigation settlement upfront payment

$ 2,000,000

Litigation settlement amount for first two installments

5,000,000

$ 5,000,000

Litigation settlement amount for remaining installments

6,000,000

6,000,000

United Health Group Settlement Agreement | Accrued Expenses And Other Current Liabilities

Commitment and Contingencies [Line Items]

Remaining accrual balance

12,000,000

12,000,000

United Health Group Settlement Agreement | Other Long Term Liabilities

Commitment and Contingencies [Line Items]

Remaining accrual balance

6,000,000

6,000,000

SDNY Civil Settlement Agreement

Commitment and Contingencies [Line Items]

Contractual obligation

$ 19,400,000

Initial payment amount

9,100,000

9,100,000

Contractual obligation additional payment amount

4,100,000

4,100,000

Contractual obligation payment amount to date

13,100,000

13,100,000

Contractual obligation in December 2020

1,600,000

Contractual obligation in December 2021

2,000,000

Contractual obligation in December 2022

$ 2,800,000

Interest rate

1.25%

Income taxes percentage of payments related to civil settlement damages awards and tax refund, CARES Act

26.00%

Maximum acceleration amount

$ 4,200,000

Income tax discrete benefit related to net operating loss, CARES Act

$ 22,700,000

37,700,000

15,700,000

Contractual obligation initial payment installment included in additional amount

5,900,000

$ 5,900,000

SDNY Civil Settlement Agreement | Subsequent Event

Commitment and Contingencies [Line Items]

Accelerated payments

4,100,000

SDNY Civil Settlement Agreement | U.S. Federal Government

Commitment and Contingencies [Line Items]

Contractual obligation

9,700,000

SDCA Civil Settlement Agreement

Commitment and Contingencies [Line Items]

Contractual obligation

$ 16,400,000

Initial payment amount

7,700,000

7,700,000

Contractual obligation additional payment amount

3,400,000

3,400,000

Contractual obligation payment amount to date

$ 11,100,000

11,100,000

Contractual obligation in December 2020

1,400,000

Contractual obligation in December 2021

1,800,000

Contractual obligation in December 2022

$ 2,200,000

Interest rate

1.25%

Income taxes percentage of payments related to civil settlement damages awards and tax refund, CARES Act

22.00%

Maximum acceleration amount

$ 3,400,000

Income tax discrete benefit related to net operating loss, CARES Act

$ 22,700,000

$ 15,700,000

Contractual obligation initial payment installment included in additional amount

4,900,000

SDCA Civil Settlement Agreement | Subsequent Event

Commitment and Contingencies [Line Items]

Accelerated payments

$ 3,400,000

SDCA Civil Settlement Agreement | U.S. Federal Government

Commitment and Contingencies [Line Items]

Contractual obligation

$ 10,000,000

Non-Prosecution Agreement

Commitment and Contingencies [Line Items]

Maximum extension of term of agreement

24 months

Minimum

Commitment and Contingencies [Line Items]

Noncancelable operating lease term

2 years

2 years

Income taxes civil settlement damages awards and tax refund amount in single year, CARES Act

$ 5,000,000

Minimum | SDNY Civil Settlement Agreement

Commitment and Contingencies [Line Items]

Income taxes civil settlement damages awards and tax refund amount in single year, CARES Act

$ 5,000,000

Minimum | SDCA Civil Settlement Agreement

Commitment and Contingencies [Line Items]

Income taxes civil settlement damages awards and tax refund amount in single year, CARES Act

$ 5,000,000

Maximum

Commitment and Contingencies [Line Items]

Noncancelable operating lease term

4 years

4 years

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Net Minimum Payments Under Non-Cancelable Operating Leases (Details) $ in Thousands	Sep. 30, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
Remainder of 2020	$ 1,933
2021	5,476
2022	3,017
2023	1,036
2024 and thereafter	38
Total future minimum lease payments	$ 11,500

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Future Minimum Payments Under Capital Leases (Details) $ in Thousands	Sep. 30, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
Remainder of 2020	$ 145
2021	324
2022 and thereafter	47
Total future minimum lease payments	516
Less amounts representing interest	(20)
Present value of minimum capital lease payments	496
Less current portion of capital lease obligations	(399)
Capital lease obligations, net of current portion	$ 97

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Thousands	Jun. 23, 2020USD ($)$ / sharesshares	Jun. 18, 2020USD ($)$ / sharesshares	Jun. 10, 2020	Apr. 03, 2020USD ($)$ / sharesshares	Dec. 19, 2019USD ($)$ / sharesshares	Nov. 22, 2019USD ($)$ / sharesshares	Nov. 12, 2019USD ($)$ / sharesshares	Aug. 27, 2019USD ($)$ / sharesshares	Feb. 29, 2020USD ($)$ / sharesshares	Jun. 30, 2014USD ($)Appraisalshares	Jun. 30, 2020shares	Sep. 30, 2020USD ($)Vote$ / sharesshares	Sep. 30, 2019USD ($)shares	Dec. 31, 2019USD ($)shares	Mar. 31, 2020$ / sharesshares	Jun. 30, 2019shares	Mar. 31, 2019shares	Dec. 31, 2018shares	Oct. 27, 2017shares
Class Of Stock [Line Items]
Common stock authorized to issue												350,000,000		300,000,000
Preferred stock, shares authorized												10,000,000		130,155,000
Number of vote per share of common stock held | Vote												1
Proceeds from issuance of common stock, net | $												$ 90,344	$ 530
Deferred offering costs | $														$ 1,100
Stock repurchased during period												3,474,572		3,474,572
Stock value repurchased during period | $												$ 18,771		$ 18,771
Stock split			0.162
Accumulated deficit | $												465,746		348,478
Amount received in exchange for issuance of shares of preferred stock | $												$ 21,307	$ 24,967
August 2019 Financing
Class Of Stock [Line Items]
Preferred stock dividends, shares												4,017,512
Increase in accumulated deficit | $														13,100
Exchange Agreement
Class Of Stock [Line Items]
Exchange ratio of shares								3.20%
Accumulated deficit | $														27,600
November Series B Preferred Stock Purchase Agreement
Class Of Stock [Line Items]
Increase in accumulated deficit | $														$ 36,400
Series B Preferred Stock Purchase Warrant | August 2019 Financing
Class Of Stock [Line Items]
Preferred stock, shares issued								9,090,910
Shares issued, price per share | $ / shares								$ 2.75
Consideration paid | $								$ 25,000
Amended underlying preferred stock purchase warrant								1,416,431											1,818,182
Series B Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized												0		126,035,000
Preferred stock, shares issued				4,444,444					5,066,666			0		101,867,405
Shares issued, price per share | $ / shares				$ 2.25
Consideration paid | $														$ 102
Amount received in exchange for issuance of shares of preferred stock | $				$ 10,000					$ 11,400
Shares issued, price per share | $ / shares									$ 2.25
Preferred stock, shares outstanding												0		101,867,405
Series B Preferred Stock | August 2019 Financing
Class Of Stock [Line Items]
Stock split												1.28
Stock split, description												1.28-for-1
Series B Preferred Stock | Exchange Agreement
Class Of Stock [Line Items]
Number of shares issued on conversion/exchange								35,664,240
Series B Preferred Stock | November Series B Preferred Stock Purchase Agreement
Class Of Stock [Line Items]
Preferred stock, shares issued							11,111,111
Amount received in exchange for issuance of shares of preferred stock | $							$ 25,000
Shares issued, price per share | $ / shares							$ 2.25
Additional shares of preferred stock issued							13,985,993
Series B Preferred Stock | November Series B Preferred Stock Purchase Agreement | Series B Preferred Stock Purchase Warrant Issued and Outstanding
Class Of Stock [Line Items]
Stock split							1.22
Stock split, description												1.22-for-1 stock split
Conversion price and exercise price of preferred stock and preferred stock purchase warrants | $ / shares							$ 2.75
Reduction in conversion price and exercise price of preferred stock and preferred stock purchase warrants | $ / shares							$ 2.25
Adjusted preferred stock purchase warrant to purchase shares of preferred stock							2,222,222
Series B Preferred Stock | Additional Equity Financing
Class Of Stock [Line Items]
Preferred stock, shares issued					11,111,111	2,722,222
Amount received in exchange for issuance of shares of preferred stock | $					$ 25,000	$ 6,100
Shares issued, price per share | $ / shares					$ 2.25	$ 2.25
Series B Preferred Stock | Credit Agreement Amendment
Class Of Stock [Line Items]
Preferred stock, shares issued															967,130
Shares issued, price per share | $ / shares															$ 2.25
Series A-1 Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized							0
Preferred stock, shares outstanding							0
Series A-1 Preferred Stock | Exchange Agreement
Class Of Stock [Line Items]
Shares outstanding								1,500,000
Exchange ratio of shares								1.20%
Minimum | August 2019 Financing
Class Of Stock [Line Items]
Convertible conversion and exercise price | $ / shares												$ 2.75
Maximum | August 2019 Financing
Class Of Stock [Line Items]
Convertible conversion and exercise price | $ / shares												$ 3.53
Repurchase Program
Class Of Stock [Line Items]
Percentage of equity interest repurchased by certain employee										25.00%
Stock repurchased during period										800,000
Stock value repurchased during period | $										$ 6,000
Repurchase Program | Minimum
Class Of Stock [Line Items]
Reasonable period of time to hold the shares under the program										6 years
Number of common stock appraisal valuations covered | Appraisal										2
Common Stock
Class Of Stock [Line Items]
Shares outstanding											50,022,606	50,450,849	8,447,926	8,451,415	8,508,144	8,397,066	8,381,130	8,112,581
Number of shares issued on conversion/exchange		33,443,562									1,250,000
Number of shares issued to an adjustment in the conversion rate		2,045,522
Common Stock | Exchange Agreement
Class Of Stock [Line Items]
Number of shares issued on conversion/exchange								4,810,651
IPO | Common Stock
Class Of Stock [Line Items]
Common stock issued and sold	6,666,667	6,666,667
Shares issued, price per share | $ / shares	$ 15	$ 15
Proceeds from issuance of common stock, net | $	$ 88,700	$ 88,700
Underwriting discounts and commissions | $		7,000
Other offering expenses | $		$ 4,300
IPO | Common Stock | Series B Preferred Stock Purchase Warrant
Class Of Stock [Line Items]
Adjusted preferred stock purchase warrant to purchase shares of preferred stock		400,160

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Preferred Stock Shares Authorized, Shares Issued and Outstanding, Per Share Price and Liquidation Preference (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Shares Authorized	10,000,000	130,155,000
Shares Issued and Outstanding		105,987,405
Aggregate Liquidation Preference		$ 231,202
Series A
Class Of Stock [Line Items]
Shares Authorized	0	4,120,000
Shares Issued and Outstanding		4,120,000
Per Share Price at Issuance		$ 0.48543
Aggregate Liquidation Preference		$ 2,000
Series B
Class Of Stock [Line Items]
Shares Authorized	0	126,035,000
Shares Issued and Outstanding		101,867,405
Per Share Price at Issuance		$ 2.25000
Aggregate Liquidation Preference		$ 229,202

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Reserved Shares of Common Stock, On An As-if-converted Basis, for Future Issuance (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Common stock shares reserved for future issuance	$ 9,235,767	$ 34,663,975
Series A Preferred Stock
Class Of Stock [Line Items]
Common stock shares reserved for future issuance		13,213,254
Series B Preferred Stock
Class Of Stock [Line Items]
Common stock shares reserved for future issuance		16,488,731
Series B Preferred Stock Purchase Warrant
Class Of Stock [Line Items]
Common stock shares reserved for future issuance		359,699
Common Stock Warrant
Class Of Stock [Line Items]
Common stock shares reserved for future issuance	400,160
Restricted Stock Units Outstanding
Class Of Stock [Line Items]
Common stock shares reserved for future issuance	1,194,077	322,608
Outstanding Options to Purchase Common Stock
Class Of Stock [Line Items]
Common stock shares reserved for future issuance	3,531,577	2,561,866
Available for Future Issuance under Equity Incentive Plan
Class Of Stock [Line Items]
Common stock shares reserved for future issuance	$ 4,109,953	$ 1,717,817

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Mar. 04, 2020	Mar. 31, 2019	Feb. 28, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 900	$ 3,374	$ 631	$ 8,455	$ 1,783
Weighted-average grant date fair value of options granted				$ 6.51	$ 7.42
Unrecognized compensation cost related to unvested stock options expected to be recognized amount		$ 12,200		$ 12,200		$ 4,100
Unrecognized compensation cost related to unvested stock options expected to be recognized over remaining weighted average vesting period				3 years 3 days		2 years 8 months 8 days
2018 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grant								1,100,000	700,000
Second Amended and Restated 2012 Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options issuable under the plan									0
2015 Consultant Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options issuable under the plan									0
Second Amended and Restated 2018 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grant						2,700,000
Third Amended and Restated 2018 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grant							7,600,000
2018 Third Amended Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grant		4,109,953		4,109,953

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Options Activity under Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options Outstanding Balance at December 31, 2019	2,561,866
Stock Options Outstanding Options granted	1,757,170
Stock Options Outstanding Options exercised	(505,852)
Stock Options Outstanding Options forfeited/cancelled	(281,607)
Stock Options Outstanding Balance at September 30, 2020	3,531,577
Stock Options Outstanding Vested and expected to vest at September 30, 2020	3,531,577
Stock Options Outstanding Vested and exercisable at September 30, 2020	1,674,215
Weighted-Average Exercise Price Balance at December 31, 2019	$ 9.01
Weighted-Average Exercise Price Options granted	10.23
Weighted-Average Exercise Price Options exercised	1.14
Weighted-Average Exercise Price Options forfeited/cancelled	11.31
Weighted-Average Exercise Price Balance at September 30, 2020	9.01
Weighted-Average Exercise Price Vested and expected to vest at September 30, 2020	9.01
Weighted-Average Exercise Price Vested and exercisable at September 30, 2020	$ 7.98
Weighted-Average Remaining Contractual Term (in years) Balance at September 30, 2020	7 years 8 months 1 day
Weighted-Average Remaining Contractual Term (in years) Vested and expected to vest at September 30, 2020	7 years 7 months 20 days
Weighted-Average Remaining Contractual Term (in years) Vested and exercisable at September 30, 2020	5 years 9 months 21 days
Aggregate Intrinsic Value Balance at September 30, 2020	$ 3,965
Aggregate Intrinsic Value Vested and expected to vest at September 30, 2020	3,965
Aggregate Intrinsic Value Vested and exercisable at September 30, 2020	$ 3,744

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Assumptions used to Determine Fair Value of Stock Options Granted (Details)	9 Months Ended
	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.40%
Risk-free interest rate, maximum	1.70%
Expected volatility, minimum	57.00%
Expected volatility, maximum	71.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)	4 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)	6 years 3 months 18 days

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 900	$ 3,374	$ 631	$ 8,455	$ 1,783
Cost of Sales
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		311	59	749	161
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		815	216	2,327	598
Selling and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		444	128	1,329	379
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		$ 1,804	$ 228	$ 4,050	$ 645

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2020
Income Tax [Line Items]
Effective tax rate	0.00%		0.00%
Income tax discrete benefit related to net operating loss CARES Act		$ 37,700,000
Income taxes percentage of payments related to civil settlement damages awards and tax refund CARES Act		65.00%
Income tax refund related to net operating loss CARES Act	$ 15,700,000		$ 38,400,000
Maximum
Income Tax [Line Items]
Net operating loss carryback period in CARES Act			5 years
Testing period for ownership change			3 years
Minimum
Income Tax [Line Items]
Income taxes civil settlement damages awards and tax refund amount in single year CARES Act		$ 5,000,000
Percentage of shift in stock ownership to determine whether ownership change occurred			50.00%
Percentage of shareholders ownership			5.00%

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Potentially Dilutive Securities Not Included in Calculation of Diluted Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted loss per share	5,125,814	26,582,603
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted loss per share	3,531,577	2,571,297
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted loss per share	1,194,077	316,481
Common Stock Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted loss per share	400,160
Series A Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted loss per share		13,213,254
Series B Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted loss per share		10,187,272
Series B Preferred Stock Purchase Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted loss per share		294,299